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Abstract
L-Tryptophan is an essential amino acid and the least abundant amino acid in humans.
An understanding of the metabolism of L-tryptophan is therefore physiologically
important. The enzyme indoleamine 2,3-dioxgyenase (IDO) catalyses the first, and rate
limiting, step in the major pathway of tryptophan metabolism, the kynurenine pathway.
The physiological role of IDO is not fully understood, but is of great interest because
IDO is a widely distributed enzyme in humans and can alter the levels of tryptophan,

which is vital for cell growth. Induction of IDO may therefore have a protective role in
bacterial, viral and protozoan infections. Additionally, tryptophan metabolism via the
kynurenine pathway produces a number of compounds that are neurotoxic and have
been implicated in neurodegenerative disease. Products of this pathway have also been
shown to be involved in lens aging and possibly age-related cataract formation.
Although implicated in a number of disease processes, the exact function of IDO is
poorly understood. The elucidation of the structure of this important human enzyme

will assist in determining its function in the body. Structural analysis will aid the des

of specific inhibitors that may contribute to the understanding of the pathophysiology o
provide treatment leads for the diseases in which the kynurenine pathway has been
implicated.

Human IDO can be isolated from tissues such as the placenta, but only in small
quantities. Thus a reliable and efficient source of functional IDO was required to

provide sufficient protein for structural analysis. This study details the development of
a recombinant expression system for human IDO. The expression construct,
Escherichia coli EC538 (pREP4, pQE9-IDO) produced a full-length human IDO

xiv

protein, with a N-terminal hexahistidyl tag. The molecular weight of the recombinant
protein product was determined to be 46, 976 Da and it has a specific activity of 149
Hmole kynurenine produced per hour per mg of enzyme, with L-tryptophan as the
substrate. The recombinant protein contained 0.8 moles of heme per mole of enzyme
and the isoelectric point was determined to be 7.1. As with the native enzyme,
recombinant IDO exhibited characteristic maxima at 406 and 630 nm by ultravioletvisible spectroscopy and these were shifted to 420 and 560 nm in the reduced form.
The recombinant enzyme used L-tryptophan, D-tryptophan and 5-hydroxy-L-tryptophan
as substrates. The Km values were determined to be 20 ,uM for L-tryptophan, 5 mM for
D-tryptophan and 440 uM for 5-hydroxy-L-tryptophan. The maximum turnover rates
(Vmax) for these substrates were 120 (L-tryptophan), 160 (D-tryptophan) and 5.3 (5hydroxy-L-tryptophan) moles of kynurenine produced per hour per mole of enzyme.
These were similar to the native enzyme, indicating that the addition of a hexahistidyl
tag did not significantly affect the catalytic activity of the enzyme. It could be
concluded from the characterisation of this purified recombinant protein that it was
essentially identical to the native human enzyme, in terms of spectroscopic properties,
cofactor dependency, substrate specificity and molecular activity. Circular dichroism
spectroscopy showed that recombinant human IDO consists of a large random coil
component, with approximately 30% alpha helical and 10% beta sheet structure. Initial
X-ray crystallographic studies of the recombinant protein resulted in the formation of
small crystals, which is promising in the quest to solve the 3-dimensional structure of
human IDO.

To identify amino acid residues important in substrate or heme binding in IDO, sitedirected mutagenesis was undertaken. It had been proposed that a histidine acts as the

xv

proximal h e m e ligand in I D O . Mutation of the only three highly conserved histidines in
EDO species, His , His and His , was therefore conducted. Of these, only His

was shown to be essential for heme binding, indicating that this histidine residue may be
the proximal ligand, and suggesting that neither His nor His acts as the proximal
ligand. Site-directed mutagenesis of Asp274 compromised the ability of IDO to bind
heme. This indicates that Asp274 may also coordinate to the heme and that it could be
the distal ligand or be essential in maintaining the conformation of the heme pocket.

This is the first study to show that both His346 and Asp274 are essential for the binding of
heme in human EDO.

Site-directed mutagenesis also facilitated the production of a truncated IDO protein.
This truncated IDO maintained enzymatic activity, indicating that the C-terminal region
of IDO is not required for activity and may be a flexible region. The removal of this
region in the truncated recombinant human IDO may be beneficial for future X-ray
crystallographic studies.

An expression and purification system has therefore been established that produces an
enzymatically active recombinant EDO, which is comparable to the native enzyme.
Access to this enzyme will greatly aid the design of EDO inhibitors, which may assist in
the elucidation of the role(s) of IDO in humans. Site-directed mutagenesis has
identified two residues, His303 and Asp274 that are essential for heme binding, and thus
enzymatic activity, in human IDO.

xvi

Chapter 1
Introduction to
indoleamine 2,3
dioxygenase

Chapter 1: Introduction to indoleamine 2,3-dioxygenase

1. Introduction to indoleamine 23dioxveenase
There are many and varied research approaches to extending knowledge into the
aetiology of diseases and in the development of treatment leads. Understanding the
structure and function of enzymes is one powerful approach. The enzyme indoleamine
2,3-dioxygenase (IDO) plays a physiologically important role in the human body as it
can control the levels of the essential amino acid L-tryptophan, and a number of its
neurotoxic metabolites. To date, little is known on the structure of IDO. Increasing the
structural information on IDO will extend our fundamental knowledge of this important
human enzyme. It will also aid the design of small molecules that can regulate IDO
activity. Such molecules will allow the role of EDO in various disease states to be
investigated more extensively and may provide lead compounds for therapeutic use.
This chapter will provide an overview of tryptophan metabolism and the role that EDO

plays. It will also introduce the historical, enzymatic and known structural properties o
EDO, diseases to which it has been linked, and its known inhibitors.

1.1 Tryptophan metabolism

L-Tryptophan, (2-amino-3-indolepropionic acid), is an amino acid that has a unique
structure, containing an indole nucleus in the side-chain. With an occurrence of
approximately 1% of the total amino acid content of proteins in the body, it is the least
abundant amino acid in humans. As there is no pathway for the synthesis of

-l-
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L-tryptophan in humans it is described as an essential amino acid and therefore must be
supplied in the diet.

Protein Synthesis

CY%
(i)

H

(ii)

Tryptamine

>
(iii)

H
H

^

L- Tryptophan
Kynurenine Pathway
(refer to Figure 1.2)

1—COOH

5-Hydroxytryptophan

5-Hydroxytryptamine
(Serotonin)

N-Acetylserotonin

Melatonin

Figure 1.1 Metabolic fates of tryptophan. Metabolic pathways of the essential amino acid L-tryptophan
in humans: (i) indicates the incorporation of L-tryptophan into proteins; (ii) the decarboxylation to form
tryptamine; (iii) outlines the serotonin pathway and (iv) refers to the major metabolic pathway, the
kynurenine pathway, which is shown in Figure 1.2.

Once ingested, tryptophan is readily metabolised by one of four pathways (Figure 1.1).
It can be (i) incorporated into proteins, which accounts for up to 80% of cellular
tryptophan in some tissues [1]; (ii) decarboxylated to tryptamine, which is a
neurotransmitter implicated in a variety of neural functions, such as pain response and
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dose dependent constriction of smooth muscle [2]. In humans the two major catabolic
pathways of tryptophan are the serotonin (iii) and the kynurenine (iv) pathways. Only
approximately 2-3% of all dietary tryptophan is metabolised by routes (i) - (iii).

Historically the conversion of tryptophan to serotonin was the major research focus
because serotonin is an important neurotransmitter in the central nervous system [3-5].
The first step of the serotonin pathway is the hydroxylation of tryptophan at the
5-position to form 5-hydroxytryptophan [3]. 5-Hydroxytryptophan is then
decarboxylated, by the vitamin B6 dependent enzyme aromatic L-amino acid
decarboxylase to 5-hydroxytryptamine, otherwise known as serotonin [5]. As well as
being a neurotransmitter, serotonin plays multiple regulatory roles in the nervous
system [6]. It is involved in regulating mood, anxiety and sleep and has been implicated
in many clinical conditions such as migraines, schizophrenia and depression. In the
pineal gland serotonin is iV-acetylated and then Omethylated, forming 5-methoxy-iVacetyltryptamine (melatonin) [4]. Melatonin is a hormone responsible for lightening
skin pigmentation and maintaining the circadian rhythm [6].

1.2 The kynurenine pathway

The major catabolic pathway for tryptophan, the kynurenine pathway, was first
described in 1947 [7] and accounts for approximately 90% of tryptophan catabolism in
mammalian peripheral tissues [1, 3]. The kynurenine pathway (Figure 1.2) is
responsible for the production of nicotinamide dinucleotide (NAD), an essential
electron carrier in catabolic reactions such as glycolysis [4].

-3-
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The first and rate-limiting step of the kynurenine pathway is the oxidative cleavage of
the 2,3-double bond of the tryptophan indole ring and the incorporation of molecular
oxygen or superoxide anion. Two enzymes are capable of catalysing this reaction,
tryptophan 2,3-dioxygenase (TDO) [1.13.1.12] and indoleamine 2,3-dioxygenase (IDO)
[1.13.11.17]. The cleavage product, N'-formylkynurenine, is hydrolysed by a
formamidase enzyme to form kynurenine [3, 4, 8]. The overall reaction results in the
incorporation of three atoms of oxygen into the products formate and kynurenine; two
of these are inserted during the oxidation process and the third is incorporated into
formate during the hydrolysis of N'-formylkynurenine [9].

Kynurenine is the key intermediate of tryptophan metabolism in mammals [10]. After
its formation the pathway branches into three (i—iii) [3]:
(i) The major route of kynurenine metabolism takes place via oxidation of the aromatic
ring by kynurenine 3-hydroxylase [EC 1.14.13.9] to form 3-hydroxykynurenine. This
product can then be cleaved by kynureninase to give 3-hydroxyanthranilic acid, which
is then converted to quinolinic acid by 3-hydroxyanthranilic acid oxidase
[EC 1.13.11.6]. Before feeding into the ^-nicotinamide adenine dinucleotide (NAD)
pathway, quinolinic acid is converted to nicotinic acid mononucleotide by the action of
QPRTase [EC 2.4.2.19]. 3-Hydroxykynurenine, the first product of this strand, can also
be acted upon by kynurenine aminotransferase to form xanthurenic acid.
(ii) Kynureninase [EC 3.7.13] catalyses the cleavage of kynurenine to give anthranilic
acid. This step also results in the formation of the amino acid alanine.
(iii) The enzyme kynurenine aminotransferase [EC 2.6.1.7] catalyses the transamination
of kynurenine to 2-aminobenzoylpyruvate, which then loses water and undergoes

-4-
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cyclisation to kynurenic acid [1]. Kynurenic acid is a stable aromatic metabolite and is
secreted in the urine of mammals.

H0 2 C
IDO (EC 1.13.11.17)
*TOO (EC 1.13.1.12)

0 ^ "H
Formamidase
(EC 3

L-Tryptophan

Kynurenine
3-hydroxylase
(EC 1.14.13.9)

(i)

"">

K

(i«)

Kynurenine

N'-Formylkynurenine

Kynurenine
Aminotransferase
(EC 2.6.17)

(ii)
0

Kynureninase
(EC 3.7.13)

C0 2 H

C02H
NH„

N

OH
3-Hydroxy kynurenine

C0 2 H

Kynurenic acid

Anthranilic Acid

Kynureninase
(EC 3.7.13)

C0 2 H

OH
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Figure 1.2 K y n u r e n i n e pathway. T h e kynurenine pathway is the major metabolic pathway for
L-tryptophan. After the formation of kynurenine the pathway branches into three strands: (i) the
formation of intermediates leading into the N A D pathway; (ii) the cleavage of kynurenine to form
anthranilic acid; (iii) the transamination and cyclisation of kynurenine to form kynurenic acid. (Figure
modified from Bolting (1985) [3].
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The products of the major route of the kynurenine pathway, (i), have many
physiological effects. For example 3-hydroxyanthranilic acid is an antioxidant with
possible protective roles, while both 3-hydroxykynurenine and quinolinic acid are
neurotoxic [11, 12].

1.3 Tryptophan 2,3-dioxygense (TDO) and indoleamine 2,3dioxy2ense (IDO)

As previously stated, the first step of the kynurenine pathway is catalysed by either
TDO or EDO. In 1937 Kotake and Masayama isolated an enzyme from rabbit liver that
catalysed the conversion of tryptophan to N'-formylkynurenine and named it tryptophan
pyrrolase. This enzyme was later renamed tryptophan 2,3-dioxygenase (TDO) [13].

In 1967 a second enzyme that catalysed the conversion of tryptophan to kynurenine was
isolated [14]. This enzyme was purified from rabbit small intestine and was the first
report of an oxygenase that catalysed not only the formation of L-kynurenine from
L-tryptophan through the formyl intermediate, but also metabolised D-tryptophan. The
enzyme was tentatively named D-tryptophan pyrrolase, but was later renamed
indoleamine 2,3-dioxygenase (IDO).

While both TDO and IDO are capable of catalysing the oxidative cleavage of
tryptophan to N'-formylkynurenine, comparison of these two enzymes (Table 1.1)
shows them to be quite different. TDO has been located only in the liver [13] and
placenta [15], while IDO is distributed ubiquitously in extrahepatic tissues [16]. In
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humans, E D O is found in high levels in the lung, small intestine and placenta, with
moderate amounts in the spleen and stomach [17].

Table 1.1 Comparisons of indoleamine 2,3-dioxygenase (IDO) and tryptophan 2,3-dioxygenase
(TDO). Comparison of I D O and T D O ; two enzymes capable of catalysing the oxidative cleavage of
tryptophan.

Indoleamine 2,3-dioxygenase

Tryptophan 2,3-

(IDO)

dioxygenase
(TDO)

Molecular Weight (kDa)
Structure
Localisation

45

320

Monomer

Tetramer

Ubiquitous in extrahepatic tissues

Liver and Placenta

1

2

D-and L-Tryptophan,

L-Tryptophan

H e m e (unit per molecule)
Substrates

5-Hydroxytryptophan, Tryptamine,
Oxygen Source

O2 and O2-

O2

EDO is a monomeric protein with a molecular weight of approximately 45 kDa and a
sole heme prosthetic group, whereas T D O is a tetramer of 320 kDa, consisting of
80 k D a subunits and contains one heme unit per two subunits [3, 18].

TDO has an activating site, separate from the substrate-binding site. This activating
can be occupied not only by tryptophan, but also by a number of its analogues, however
these do not compete for the substrate site. There is only one substrate for the active
site of T D O , L-tryptophan [3]. E D O has a much broader specificity, and accepts D- and
L-tryptophan, tryptamine and 5-hydroxytryptophan as substrates [16]
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1.4 Indoleamine 2.3-dioxysenase

1.4.1 Isolation of IDO

A reliable method for the isolation and purification of rabbit IDO was developed in
1978 [16] based on the protocol of Yamamoto and Hayaishi [14]. After isolation, the
small intestine was sonicated and the crude extract was treated with streptomycin and
ammonium sulphate. IDO was purified from this crude extract through a number of
chromatographic steps including cation exchange chromatography (with
phosphocellulose resin), hydroxyapatite chromatography, gel filtration, isoelectric
focusing and a final gel filtration step. This protocol was widely used to provide a
source of purified rabbit intestinal EDO for further studies and typically resulted in a
500-fold purification, with an 11% yield and an activity with L-tryptophan of
171 nmoles kynurenine/h/mg protein [19].

EDO was later isolated from human placenta. The isolation and purification protocol
was similar to that developed for rabbit intestinal EDO, incorporating a number of
chromatographic steps, including phosphocellulose and hydroxyapatite
chromatography, gel filtration and isoelectric focusing. This resulted in a 10,000-fold
purification and a 0.9% yield, with a specific activity of 157 umol kynurenine/h/mg
protein using L-tryptophan as the substrate [19, 20]
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1.4.2 Primary structure of IDO

In 1989 two groups concurrently reported the primary sequence of human IDO. Tone
et al. [21] isolated the cDNA clone from a A.gt library prepared from poly (A)+ RNA
IFN-y treated HEL cells with a monoclonal antibody to human IDO. Dai et al. also
used poly (A)+ RNA, but from HuLFN-y infected human fibroblasts [22]. The human
IDO cDNA contained an open reading frame of 1209 nucleotides that encoded a protein
of 403 amino acids, with a molecular weight of 45,324 Da. The IDO gene was
determined to span 15 kilobase pairs with 10 exons and was present in a single copy
haploid genome [23]. The gene was localised to the peri-centromeric region of human
chromosome 8 [24, 25].

Using human EDO cDNA as a probe, the murine EDO gene was isolated from mouse

rectal cancer cells. The gene had an open reading frame of 1221 nucleotides, encodin

a protein of 407 amino acids, with a molecular weight of 45,639 Da. Mouse EDO has an
overall 61% homology to human EDO. Residues 101-184 were highly homologous to
residues 96-181 of human EDO with 89% identity [26]. Primers based on the mouse
EDO sequence were then used to probe for rat EDO. The gene for rat IDO is 1221
nucleotides long, encoding 407 residues, with a mass of 45,830 Da [27]. The rat IDO
gene has 91% identity to mouse and 75% identity to human IDO. To date the primary
structure of rabbit IDO has not been determined.

Although it is a hemoprotein, IDO has very little sequence homology to other heme
proteins such as hemoglobin, myoglobin or cytochrome p450 and has only
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approximately 10% identity to TDO. In 1992 Suzuki et al. [28] reported the
identification of a myoglobin isolated from the red muscle of abalone, Sulculus
diversicolor aquatilis, which showed no significant homology with other globins, but
had 35% identity with IDO.

Figure 1.3 The amino acid identity and similarity of various proteins compared to h u m a n IDO. The
blue bars indicate amino acid identity and the red bars indicate amino acid similarity to the human I D O
sequence [21]. Proteins aligned are mouse [26] and rat [27] IDO, and the IDO-like myoglobin proteins
(Myo) isolated from Sulculus diversicolor aquatilis (S. Div) [28], Nordotis madaka (Nord) [29], Turbo
cornutus (Turb) [30] and Omphalius pfeifferi (Omph) [31] as well as human [18], mouse (AC P48776)
and rat [32] T D O .

The oxygenated reaction intermediate of IDO is not stable, so IDO cannot serve as an
oxygen carrier. However, the Sulculus myoglobin is sufficiently stable such that it can
act as an oxygen carrier. It was therefore proposed that in the course of molecular
evolution the Sulculus myoglobin had to mask enzyme activity in order to function in an
analogous manner to myoglobin. In agreement with this hypothesis, the Sulculus
myoglobin has no enzyme activity but, in the presence of tryptophan, the autoxidation
rate of oxymyoglobin was greatly accelerated. This suggests that a tryptophan-binding
site remains near or in the heme cavity as a relic of evolution [28, 33, 34]. An IDO-like
-10-
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myoglobin has also been isolated from Nordotis madaka [29], the gastropod mollusc
Turbo cornutus [30] and Omphalius pfeifferi [31]. The identity and similarity of the
amino acid composition of these myoglobins, TDO and IDO isolated from various
species, compared with human, EDO is outlined in Figure 1.3.

1.4.3 Catalytic properties of IDO

EDO is a cytosolic, monomeric protein [16] with protoheme DC as its sole prosthetic
group [35, 36]. One mole of the purified rabbit enzyme contains 0.8 mole of protoheme
IX [16]. The ultraviolet (UV)-visible spectrum of EDO is typical of a high-spin ferric
(Fe ) hemoprotein, having absorbance maxima at 405 nm in the soret region and 500
and 632 nm at pH 6 [37]. Purified IDO is an inactive ferric (Fe3+) enzyme and needs
methylene blue and ascorbic acid for activity in vitro [14]. Some enzymes, such as
glutathione reductase and xanthine oxidase, which generate superoxide anion (O2), can
replace ascorbic acid. Methylene blue, however, which is thought to act as an electron

carrier, has not been able to be replaced by any natural co-factors, metals or other dye
except for toluidine blue [19].

Further investigations into the catalytic requirements of EDO have shown that it is a
unique heme containing oxygenase. It requires and utilises the superoxide anion, a
univalent reduced molecular oxygen, in addition to molecular oxygen, for the initiation
of the reaction and for maintenance of the catalytic cycle during the steady state
[19, 38]. The role of superoxide in the catalytic requirements of IDO was inferred from
five separate observations [19, 35, 39-41].

-11-

Chapter 1: Introduction to indoleamine 2,3-dioxygenase

(i) The superoxide anion, by itself, could support EDO activity;
(ii) E D O activity is inhibited by superoxide dismutase, which removes available O2";
(iii) Incorporation of l s O into the reaction products occurs following the addition of
1 8 n -.

(iv) Intracellular I D O activity is enhanced by diethyldithiocarbamate, an inhibitor of
superoxide dismutase;
(v) The native, ferric (Fe ) form of I D O binds to the superoxide anion to form the
oxygenated enzyme (Fe3+02~), which reacts with the substrate to form the end product.

1.5 Recombinant expression systems for human IDO

As previously stated human IDO has been purified from placental tissue [20]. The
purification procedure however, was complex (requiring a 10,000-fold purification) and
resulted in a small protein yield. In order to gain access to larger quantities of h u m a n
E D O a recombinant expression system was developed in which full length E D O c D N A
was cloned into the plasmid p G E X - I X T [42]. The plasmid p G E X - 1 XT-EDO was
transformed into E. coli Y A 2 1 cells and expressed I D O as a fusion protein, with a
glutathione-S-transferase (GST) tag. The protein was purified using a gluthathione
Sepharose 4 B column, which resulted in a yield of 7.5 mg/L of fusion protein. The
G S T tag was then cleaved from the recombinant IDO, affording 2.3 mg/L.

The

recombinant protein was, however, contaminated with small amounts of fusion protein
and degradation products. Overall this achieved a 42-fold purification with a 2 7 % yield
and a specific activity of 30.4 umoles kynurenine/h/mg protein with L-tryptophan as the
substrate [42]. Southan et al. [43] also used this expression system and showed that the
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purified enzyme was unstable, losing 70% of activity after 24 h when stored at -20°C.
This enzyme was not ideal, due to both its instability and its relatively low activity
(20%) compared with that of the native enzyme (157 umoles kynurenine/h/mg protein)
[20].

1.5.1 The hexahistidyl tagged expression system

There are several procedures that exploit a particular property of a protein moiety, or a
short amino acid sequence 'tag' fused to the recombinant protein, to aid purification.
These include the GST fusion system used with gluthathione-Sepharose beads [44] as
described above; the protein-A fusion system combined with immunoglobin columns
[45]; epitope-tagging used together with specific antibodies [46] and histidine tagging
techniques for metal chelate affinity chromatography [47].

Immobilised metal-affinity chromatography was initially used for the fractionation of
proteins rich in residues involved in metal binding (histidines and reduced cysteines)
[48]. Hochuli et al. developed a novel nitrilotriacetic acid (NTA) adsorbent, which
when charged with Ni has remarkable selectivity for protein and peptides containing
neighbouring histidine residues [47]. The fusion of six sequential histidines to a

recombinant protein facilitates a high affinity interaction and, coupled with purificatio
using Ni-NTA resin, is a powerful technique for the purification of recombinant
proteins. The hexahistidyl (6His) tagged protein binds to the resin through the histidine
imidazole ring and binding is resistant to high salt, anionic detergents and 6 M
guanidine hydrochloride. The tagged protein is easily eluted in the buffer of choice
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containing imidazole at physiological pH or by protonation of the amino acid side chain
[48, 49].

Several cloning vectors for different expression systems that incorporate a hexahistidyl
tag are commercially available. These include vectors for bacteria (Qiagen and
Invitrogen) and transient and stable expression in mammalian cells (Invitrogen).

There are many advantages of the 6His expression system over other systems, such as
the GST fusion system [48, 49]. These include the high capacity of the resin (2-10 mg
of tagged protein per mL of resin), the wide range of buffer systems that can be used
and the ease of protein elution. Also the 6His tag is short and protease cleavage is
usually not necessary for obtaining a functional recombinant protein. This methodology
was therefore chosen for expression of recombinant human IDO in this study.

1.6 IDO and disease states

In healthy humans, products of the kynurenine pathway exist in low nanomolar
concentration and exert little if any physiological effect [50]. The over-expression of
EDO, however, leads to increased concentrations of kynurenine pathway metabolites,
most notably the neuroactive metabolites 3-hydroxykynurenine and quinolinic acid.
Elevated levels of these metabolites have been linked to neurological conditions,
including cerebral malaria [51], AIDS dementia complex [52-54], Alzheimer's disease
[55, 56] and Huntington's disease [55, 57]. Other conditions such as age-related
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cataract [58, 59], septicaemia [60] and Lymes disease [61] are also related to
kynurenine pathway metabolites.

1.6.1 Induction of IDO

EDO is systemically, as well as locally, induced under a variety of pathological
conditions, including viral [62-65], bacterial [38, 66] and protozoan infections [51],
allograft rejection [67, 68] and tumor regression [69-71]. Under these conditions, the
body increases the production of the cytokine interferon-y (IFN-y), which in turn
induces EDO. The relationship between E^N-y and EDO was reviewed by Taylor and
Feng [13]. Two IFN-stimulated response elements (ISRE) and at least one IFNactivated sequence (GAS) are present in the EDO gene to regulate its expression [72,
73]. The primary role of EDO induction in infectious disease appears to be to suppress
the growth of pathogens and this may be by the depletion of L-tryptophan.

IFN-y mediated EDO induction has recently been examined by Mackenzie et al. [74].
These authors found that induction of EDO by IFN-y resulted in growth inhibition of
Toxoplasma and Chlamydia spp. as well as tumor cells. IDO induction restricting
tumor growth has also been reported by Burke et al. [69], who showed that
L-tryptophan depletion caused by IFN-y induction of EDO may be a contributor to a
multifactorial growth inhibition of tumour cells.

Nitric oxide is an important mediator able to inhibit EDO activity in IFN-y primed
mononuclear phagocytes in vitro [75]. The mechanism of inhibition, however, is
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unclear and may involve direct interaction of nitric oxide with the heme iron or the
superoxide anion.

1.6.2 Neurodegenerative disease and IDO

There has been increasing interest in the role of the kynurenine pathway metabolites in
neurodegenerative disorders. Kynurenine, 3-hydroxykynurenine, quinolinic acid and
kynurenic acid are all present in the central nervous system. 3-Hydroxykynurenine is
toxic to brain neurons at levels as low as 1 uM and increased levels have been observed
in neurodegenerative diseases such as AIDS dementia complex [52-54] and
Huntington's disease [55, 57].

Quinolinic acid is an endogenous N-methyl-D-aspartate (NMDA) agonist and kynurenic
acid is an antagonist of NMDA receptors [76, 77]. NMDA receptors are a subclass of
the glutamate receptor and their activation under physiological conditions is intimately
associated with processes of memory and learning, neuronal death and
neurodegenerative disorders [78]. Quinolinic acid therefore may mediate the effects of
neuronal damage and dysfunction, whilst kynurenic acid may disrupt amino acid
neurotransmission [79]. Stone [1, 79] has extensively reviewed the neuropharmacology
of quinolinic acid. It is consistently toxic to human neurons in vitro at 5 and 10 mM
and there is some evidence that it is toxic at concentrations of 1 mM [80] and at
micromolar levels [81].
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1.6.2.1 AIDS dementia complex and IDO

Infection with human immunodeficiency virus (HIY)-l, leading to ADDS, is frequently
associated with neurological deficits referred to as AIDS dementia complex [52, 80],
which occurs in 20-30% of patients with advanced HTV disease [82]. The symptoms of
AIDS dementia complex can be grouped into three areas, cognitive, motor function and
behavioural and include poor concentration, memory lapses and clumsiness [82].

Increased production of neurotoxic kynurenine metabolites, such as quinolinic acid, has
been proposed as a mechanism for these neurological deficits [83]. It has been shown
that the kynurenine:tryptophan ratio increases with HTV infection [84] and that

quinolinic acid levels are increased in the cerebrospinal fluid of non-dementia (3.5-fo
and dementia (20-fold) AIDS patients [53]. These levels correlate with the degree of
neuropsychological deficits observed in these patients. Experiments with foetal tissue
showed that chronic exposure of neurons to the levels of quinolinic acid found in the

cerebrospinal fluid of affected patients, was toxic and led to changes consistent with t
neuropathy of ADDS dementia complex patients [80, 81].

Sardar et al. examined EDO activity in post-mortem human brain tissue and found that
IDO activity was increased, but not significantly, in the non-dementia AIDS group or

the control, however there was a significant increase in IDO activity in the subjects wi
HTV-1 associated dementia [52]. It has therefore been shown that both quinolinic acid
and EDO levels are increased in patients with AEDS dementia complex.
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The mechanism of EDO induction following HTV infection is still unclear, however, it
has been found that HTV infection leads to an increase in cytokines, including
interleukin-1 and -6 and IFN-a and -y. IFN-y is capable of inducing EDO [52].
Induction of EDO and subsequent increases in the levels of kynurenine metabolites, by
selected HTV-1 strains, has been reported [85, 86]. This HIV-1 induction of IDO was
not observed in all HTV-1 strains, and this induction appeared to be mediated by a
transient production of EFN-y in human monocyte-derived macrophages.

1.6.2.2 Cerebral malaria and IDO

Cerebral malaria is the most common fatal complication of Plasmodium falciparium
infection. In a recent study, cerebrospinal fluid of patients with cerebral malaria was
found to have large increases in the concentration of quinolinic acid compared to the
control populations [87]. The pathogenesis of cerebral malaria remains unresolved,
however, IFN-y knockout mice did not develop cerebral malaria and there was no EDO
induction in the IFN-y deficient mice. This indicates that IDO is induced by IFN-y,
leading to increased quinolinic acid levels.

In a murine model IDO activity in the brain was found to be low or absent in noncerebral malaria and control mice, but strongly induced in cerebral malaria mice at day
6-7 post infection [51]. This induction of IDO did, however, occur in non-cerebral

malaria mice, at day 14-17 post infection. This indicates that IDO induction in the brai
was not solely responsible for the cerebral malaria symptoms. The quinolinic acid to

kynurenic acid ratio was high in the cerebral malaria brain compared to the non-cerebral
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malaria brain [77]. The ratio of quinolinic acid to kynurenic acid may be responsible
for the convulsions associated with murine cerebral malaria [51].

1.6.2.3 Huntington's disease and IDO

Huntington's disease is a genetic neurodegenerative disorder that affects approximately
7 people per 100,000 in Australia. Symptoms include progressive cognitive impairment
and involuntary movements, with the disease eventually leading to severe incapacitation
and death, approximately 15-25 years after onset [88]. Huntington's disease is
characterised by extensive neuronal loss in the caudate nucleus and putamen, with
relative sparing of the rest of the brain [89]. 3-Hydroxykynurenine has been linked to
Huntington's disease, with increased levels observed in the brains of affected patients
[55].

An animal model of Huntington's disease was developed by Schwarcz et al. [11] in
which kainic and ibotenic acids, neuroexcitatory and toxic amino acids of plant and

fungal origin respectively, are injected into the brain. This resulted in striatal lesions
which closely resemble the neuropathologic and neurochemical changes characteristic
of Huntington's disease. Kainic and ibotenic acids structurally resemble the
endogenous excitatory amino acids, glutamic and aspartic acids. Based on this
observation a hypothesis was proposed that hyperfunction of the body's own
excitotoxins may be related to neuronal damage in certain neuropsychiatric diseases.
Upon investigation, it was found that these amino acids exhibit only marginal
neurotoxic potency in the mature nervous system compared to the toxicity in
experimental models [11]. Quinolinic acid however, can produce axon-sparing
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neuronal lesions after intracerebral injections in rats, mimicking the effects of both
kainic and ibotenic acids in character and function [11, 88].

Although the quinolinic acid induced lesions in mice do resemble the features of post
mortem brain in Huntington's disease [11, 88, 89], the levels of quinolinic acid in post
mortem brains or cerebrospinal fluid of Huntington's patients have been shown to be
normal [76]. 3-Hydroxykynurenine, however, has been observed in increased levels in
the brains of affected patients [55] and it has been proposed that this causes a toxic
effect mediated by the generation of H2O2 [57].

It is therefore possible that kynurenine pathway metabolites have a role in the aetiology
of this disorder. Schwarcz et al [11] suggest that either increased transport from the
periphery or a metabolic defect in the brain may provide an excess of quinolinic or
3-hydroxykynurenine sufficient to induce neuronal degeneration of the type found in
Huntington' s disease.

1.6.3 Age-related cataract and IDO

Cataract is defined as opacity of the ocular lens. Age-related cataract is the most
common cause of human blindness and the nuclear form is characterised by a gradual
increase in tanned/yellow colouration of the lens nucleus [58]. 3-Hydroxykynurenine, a
metabolite of the kynurenine pathway, is a UV filter compound in the human lens. UV
filters are compounds that absorb UV radiation transmitted by the cornea in the 295 to
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400nm region. Absorption of this band protects both the lens and retina from UVinduced photodamage and aids visual acuity by decreasing chromatic aberration [90].

It has been shown in vitro that 3-hydroxykynurenine [91, 92] can react with the major

lens proteins (crystallins) to produce cross-linked products, with features characterist

of those observed in age-related cataract. Furthermore, kynurenine and the lens specific
kynurenine pathway metabolites, 3-hydroxykynurenine glucoside, have been shown
in vivo to cross-link lens proteins.

It has been reported that EDO is present in the bovine lens [93], this however remains to
be confirmed. Free tryptophan was shown to undergo metabolism in the human lens by
Malina and Martin [94]. EDO was determined to be the enzyme responsible for this
metabolism. Takikawa et al. [95] showed EDO is present in the human lens as the first
and rate-limiting enzyme of the kynurenine pathway. It therefore may be possible to
prevent or delay the onset of age-related cataract by lowering the levels of these
kynurenine pathway metabolites in the lens, by inhibiting EDO.

1.6.4 Foetal rejection and IDO

The ability of the body to differentiate between self and non-self forms the basis of ou
immune system. A major obstacle posed to this recognition process is pregnancy.
Stemming from the idea that the body tolerates self and attacks non-self, during
pregnancy the female would recognise the foetus as non-self and attack it [96].
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There are 3 main mechanisms that could explain foetal survival [97]:
(i) Anatomic separation of the mother and foetus.
(ii) Antigenic immaturity of the foetus.
(iii) Immunological tolerance of the mother.

The first of these mechanisms is ruled out because the maternal-foetal membrane is not
an impassable barrier; foetal cells migrate into the mother in large enough
concentrations to be used in prenatal diagnostics [98]. Antigenic immaturity is ruled
out as a possible explanation because foetal and placental cells bear mature antigens,
such as surface major histocompatibility complex (MHC) molecules [98]. This brings
to the forefront the third possibility, that in some way the mother immunologically
tolerates the non-self foetus. As EDO is observed in high levels in the placenta [16, 17,
99] it was proposed that the IDO induced depletion of tryptophan may have a role in
immunological tolerance [100].

Mellor et al. has investigated the role of tryptophan metabolism in this process using a
murine model and have shown that EDO has a protective effect on the non-self foetus;
exposure of these foetuses to an EDO inhibitor (1-methyl-L-tryptophan) resulted in
rejection [100, 101]. Further work indicated that this protection was T-cell mediated
[102].

These authors proposed that the reduction in the availability of tryptophan, as a result
EDO induction, suppresses T-cell proliferation, an integral part of immunity, mediating
self/non-self recognition [98, 103]. Munn and Mellor [100-102] have extensively tested
their hypothesis in mice. Human IDO is inhibited by 1-methyl-L-tryptophan, indicating
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that the hypothesis of Munn and Mellor may be extendable to humans [104]. If

miscarriages are a result of the failure of foetal cells to induce EDO, the ability to ind
EDO may be useful in preventing miscarriages. Conversely, inhibitors of EDO might
lead to abortifacients that would work via boosting the mothers' own innate rejection
response [97].

It is known that EDO plays a role in normal physiology (e.g. production of NAD),
however, its induction has been implicated in many diseases and inhibition/regulation of
EDO may increase information into the aetiology of these diseases, or provide a means
for alleviating them. For the treatment of diseases such as cerebral malaria, AIDS
dementia complex, Alzheimer's and Huntington's disease, selective drug delivery to the
brain would be necessary. This may be achieved by developing a pro-drug form of the
inhibitor, which could cross the blood brain barrier and then be converted to the active
inhibitor. In the case of age-related cataract, selectivity could be achieved via eye
drops, which would allow for the localised usage of EDO inhibitor.

1.7 IDO inhibitors

A number of inhibitors of IDO have been reported. These can be categorised as
competitive or non-competitive. The known non-competitive inhibitors of EDO bind
directly to the heme, while competitive inhibitors compete with substrates for the
binding site.
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1.7.1 Non-competitive inhibitors of IDO

EDO is inhibited by potassium cyanide and carbon monoxide [14]. Both of these
compounds bind with a greater affinity than oxygen to the heme. This was the first
evidence to indicate that heme contained in the enzyme is involved in the catalysis of
the enzyme [14] and that the heme binding site is associated with the substrate binding
site of EDO.

Inhibition of EDO has also been reported with (3-carbolines such as norharman and
related molecules. Norharman (Figure 1.4A) has been shown to non-competitively
inhibit rabbit intestinal IDO with a K of 120 uM. It acts as a nitrogen donor ligand,
competing with oxygen, to bind directly to the heme [105]. Another non-competitive

inhibitor is brassilexin (Figure 1.4B) and this is thought to bind to the heme through th
isothiazole group [106].

A B

Figure 1.4 Non-competitive I D O inhibitors. Structure of (A) norharman and (B) brassilexin, both are
non-competitive inhibitors of indoleamine 2,3-dioxygenase (IDO).

Peterson et al. [106] investigated the inhibitory activity of a range of 3-substitutedP-carbolines and 3,6-disubstituted-p-carbolines in vitro against human
monocyte/macrophage EDO induction. They concluded that substitutions at the
3-position of the same relative size and polarity of a butyl group had the largest

-24-

Chapter 1: Introduction to indoleamine 2,3-dioxygenase

inhibitory activity. Substitutions of polar groups at the 3-position had a low inhibitory
affect because these were capable of forming strong hydrogen bonds. Inhibition was

also increased with fluorine or isothiocynate substitution at the 6-position (See Figur
1.5 depicting the (3-carboline backbone).

Figure 1.5 Non-competitive I D O inhibitor template. Template model of p-carbolines, which form the
basis of non-competitive indoleamine 2,3-dioxygenase (IDO) inhibitors.

/. 7.2 Competitive inhibitors of IDO

The first reported competitive inhibitor of EDO was 2,5-dihydro-L-phenylalanine
(Kj = 230 uM) [107]. Cady and Sono [108] looked at analogues of tryptophan as
competitive inhibitors against rabbit intestinal EDO. A problem with this approach
however, is that because IDO accepts a wide range of substrates, some possible
inhibitor compounds may also act as substrates. Three compounds were identified that
had an inhibitory effect while not acting as substrates. These were 1-methyl-DLtryptophan (K « 7 uM), (3-(3-benzofuranyl)-DL-alanine (Kj = 25 uM) and
|3-[3-benzo(Z>)thienyl]-DL-alanine (K= 70 uM) (Figure 1.6).
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Figure 1.6 Competitive I D O inhibitors. Structures of (A) 1-methyl-DL-tryptophan; (B) |3-(3benzofuranyl)-DL-alanine; (C) (3-[benzo(A)thienyl]-DL-alanine; (D) 6-chloro-DL-tryptophan and (E) 3amino-2-naphthoic acid, competitive inhibitors of indoleamine 2,3-dioxygenase (IDO).

Kerr et al. [109] showed that quinolinic acid production was inhibited by 6-chloro-Dtryptophan in a dose dependent manner in HTV-1 infected patients and preliminary work
in our laboratory has shown that 6-chloro-D-tryptophan is inhibitory against EDO in

human lens epithelial cell lines (IC50 « 230 uM). 3-Amino-2-naphthoic acid is the first

non-cc-amino acid to be reported as a competitive inhibitor of EDO. Peterson et al. [11
showed that 3-amino-2-napthoic acid inhibited human monocyte/macrophage EDO
(75% inhibition at 100 uM concentration). Work performed in our group (Takikawa
et al., unpublished results) has shown that 3-amino-2-napthoic acid inhibits IDO in
human lens epithelial cell lines (IC50 « 200 uM).

A number of tryptophan analogues have been tested with human monocyte/macrophage
EDO by Peterson et al. [110] and by Southan et al. [43], who tested tryptophan
analogues against recombinant human GST-tagged EDO [42]. These findings concluded

that the requirements for a competitive inhibitor (refer to Figure 1.7) were as follows
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(i) Integrity of the aliphatic group, indole N-H, and the C-2, C-3, C-4 and C-7
positions.
(ii) Compounds with substituents at the C-5 and C-6 position were able to bind to the
tryptophan site. With those containing electron withdrawing groups being moderate to
good inhibitors and those with electron donating groups acting as substrates.
(iii) L-isomers had higher affinity than D-isomers.

HO.C
Substitution
not preferred

,,,ni»>H

L-stereochemistry
preferred

R o o m for
substitution

Substitution
not preferred

Figure 1.7 Competitive I D O inhibitor template. Template model of competitive indoleamine 2,3dioxygenase ( I D O ) inhibitors. Structural requirements are based o n analogues of L-tryptophan, the
natural substrate.

While a number of inhibitors of EDO are known they are only moderately inhibitory and
more potent inhibitors need to be developed. Due to a lack of 3-dimensional structural
information of EDO, current inhibitor design for IDO has been approached using a
ligand based methodology i.e. potential inhibitors compounds have been screened
against purified IDO and inhibition constants and structural information have been
analysed by computer aided molecular modelling. This method allows development of
a pharmacophore (map of features deemed important for inhibition) and provides a
rational ligand-based approach to drug design. This would be aided by access to an
improved recombinant human IDO system. An improved recombinant protein would
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also aid the elucidation of the 3-dimensional structure of EDO. This would therefore
assist structure-based inhibitor design, which is the most powerful approach to drug
design.

1.8 IDO Structural Studies

1.8.1 Binding requirements of heme
Heme proteins are the most extensively studied of all metalloproteins. This is in large
part due to their intense colour and therefore the ease in which they can be seen and
isolated. All heme proteins carry iron coordinated to protoporphyrin IX (Figure 1.8).
The heme unit is charge-balanced, but if the iron is oxidised to Fe (IE), the resulting
species (hemin) carries an excess positive charge.

The four coordination sites provided by the porphyrin ring are not sufficient to satisfy
the coordination requirements of the iron. Normally groups from the protein occupy the
remaining coordination sites. The common coordinating functional groups are the
imidazole nitrogen of histidine, the phenoxide group of tyrosine, the sulphur of
methionine and cysteine and the carboxylate group of aspartic acid and glutamic acid. In
both myoglobin and hemoglobin, the heme is attached to the protein through a histidine
residue to the 5th coordination position on the iron (the proximal ligand). A second
histidine (the distal ligand) occupies space immediately above the 6th coordination
position of the iron and is coordinated through an oxygen molecule, not directly to the
iron (Figure 1.9) [6, 111-113].
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Figure 1.8 Structure of heme. The structure of heme, which contains an iron molecule coordinated to
protoporphyrin IX.

Pro+ein

Protein
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Figure 1.9 Schematic representation of a heme pocket. This schematic represents the binding of heme
in a typical metalloprotein. The porphyrin ring occupies four of the six coordination sites of iron and
amino acid residues coordinate to the other two sites. The proximal ligand, which coordinates directly,
and the distal ligand that coordinates through oxygen, are indicated using histidine residues.
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1.8.2 Equilibrium binding studies of IDO

Whilst only the primary structure of EDO has been determined [21, 22], there have been
extensive equilibrium studies undertaken to investigate the binding properties of both
substrate and oxygen and to identify the proximal and distal heme ligands.

Dioxygenases catalyse the oxidative cleavage of a substrate and, as such, both oxygen
and the substrate need to bind to the enzyme. A common property of oxygenases is that
the binding of the substrate precedes that of dioxygen and this has been shown to be the
case with TDO [114]. Hirata et al. [115] found that EDO could bind oxygen to form a

relatively stable complex that has catalytic activity. This therefore led to the question
whether the substrate or oxygen bound first to the enzyme and what was the reaction
mechanism of EDO. By determining the equilibrium constants for the different reaction
steps, it was determined that ferrous EDO binds with L-tryptophan, followed by
molecular oxygen [37]. The following mechanism (Figure 1.10) was proposed for the
EDO catalysed conversion of tryptophan to N'-formylkynurenine. The major proposed
pathway is therefore (i) IDO-Fe2+ is bound by the substrate; (ii) the IDO-Fe2+tryptophan complex is then bound by oxygen to form an EDO-Fe3+02" complex (ternary
complex); and (iii) this complex is converted to N'-formylkynurenine, releasing
EDO-Fe2+. Initial studies into this reaction scheme used EDO-tryptophan-CO as the
ternary structure model due to the instability of the IDO-tryptophan-02 ternary
complex. This problem was overcome by generating and working with the ternary O2
complex at -30°C, confirming the proposed order of the catalytic sequence in which
L-tryptophan binds, followed by dioxygen [116].
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Figure 1.10 Proposed reaction scheme of I D O . The blue coloured line indicates a possible main
catalytic pathway and the red lines indicate minor pathways. The green dotted line shows the reversible
L-tryptophan binding to the ferric enzyme. The ferric I D O first binds with the substrate (i), then oxygen,
forming the ternary complex of ferrous IDO-substrate-oxygen (ii). This then produces the product,
N'-formyUcynurenine (iii), releasing ferric IDO. (Figure modified from Sono, M., et al [37])

1.8.3 Studies of heme binding in IDO

Concurrent studies were undertaken using magnetic circular dichroism (MCD) and CD
spectroscopy to determine the properties of the heme pocket and the proximal and distal
heme ligands. These techniques were used in conjunction with electron paramagnetic
resonance, or EPR, spectroscopy. It was determined that the ferric and ferrous MCD of
IDO closely resembled that of myoglobin and horseradish peroxidase [117-119]. The
environment of the IDO heme pocket is similar to, but the size is considerably larger
than, the typical binding heme pocket of myoglobin. This is supported by the heme
pocket of IDO allowing access to the inhibitors norharman and 4-phenylpyridine [120].

-31-

Chapter 1: Introduction to indoleamine 2,3-dioxygenase

Shimizu et al. [16], based on EPR studies, proposed that the 5th (proximal) ligand of the
heme group was a nitrogen, probably from a histidine imidazole ring. The 6th (distal)
ligand in substrate free IDO was proposed to be a histidine imidazole ring nitrogen by
Uchida et al. [118, 119] and Sono and Dawson [117] based on magnetic CD
spectroscopy. Uchida et al. proposed that in the substrate bound ferric EDO the 6th
ligand was also a histidine [118, 119]. This contrasted with Sono and Dawson, who
showed that the observed changes in MCD upon substrate binding was most consistent
with a hydroxide ion being the 6th ligand in substrate bound ferric IDO [117]. The

findings of these publications, however, are consistent with both the proximal and dista
heme ligands in substrate free IDO being histidines, just as in hemoglobin and
myoglobin. Alignment of the EDO, EDO-like myoglobins and TDO sequences (See
Figure 5.1) shows that there are only three conserved histidines His16, His303 and His346.
As these residues are highly conserved it is more likely that they are involved in heme
binding. Suzuki et al. [28] proposed that the two C-terminus residues, His303 and His348

were more likely to be the proximal/distal histidines because of their proximity to each
other.

1.8.4 Endogenous regulatory site in IDO

Enzyme kinetic and spectroscopic studies of IDO inhibitors have provided evidence for
the existence of another binding site in IDO. A modified reaction scheme incorporating
this second binding site is depicted in Figure 1.11.
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Figure 1.11 Proposed reaction scheme of I D O incorporating an endogenous regulatory site.
Schematic representation of the reaction mechanism catalysed by IDO. The binding site for substrate (red
broken line) and effector (red full line) sites are represented. The dotted black lines in the binding site
indicate direct or indirect steric and/or electronic interaction amongst the bound substrate, oxygen and
effector (X) at the enzyme active site. (Figure modified from Sono, [121])

It is well established that T D O , has two binding sites: a catalytic and a regulatory site.
The second binding site in IDO appears to be for effectors and is believed to be located
near the substrate binding site and heme group. This secondary binding site might serve
as a site for a yet unknown natural cofactor or regulator of IDO [121]. Further work
needs to be undertaken to identify this binding site and effector compound(s). Such
compounds may provide lead compounds for inhibitors/activators of IDO. These
results, along with the Sono and Dawson [117] conclusions as to the proximal and distal
heme ligands, led to Sono et al. proposing a modified reaction mechanism for IDO
[121] (Figure 1.11).
-33-

Chapter 1: Introduction to indoleamine 2,3-dioxygenase

1.9 Conclusion

The kynurenine pathway is a physiologically important pathway in that it controls the

levels of tryptophan, an essential amino acid that is vital for cell growth. The ability to
control or manipulate EDO levels may be important in understanding the aetiology of, or
providing possible treatment leads in, a number of disease states. Although the primary
structure of EDO is known, information about the secondary and tertiary structure is
limited, hindering the structure-based design of inhibitors. Extensive studies into the
heme environment of the rabbit enzyme have been undertaken, however to date the
primary structure of the rabbit form has not been determined. Therefore it is hard to
correlate these studies to the structure of human EDO.

Purification of EDO from human placenta has been achieved, but is a complex procedure
that resulted in a low yield. The first recombinant human EDO, a GST-tagged protein, is
not ideal with EDO conjugated to a large protein tag, which affected EDO activity. An
efficient system for viable human EDO production therefore needs to be established
before the structure of human IDO can be determined. A source of large quantities of
enzymatically-active EDO would aid in the establishment of a more reliable in vitro
system to test lead inhibitor compounds, aiding ligand based inhibitor design. It is also
fundamental that the structure of IDO be elucidated so that potent inhibitors of EDO can
be designed and developed.
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1.10 Research Aims

The aim of this research was determine structural features of human EDO, with the
longer-term aim being to use this information to rationally design inhibitors of EDO.
This will help to determine the exact role of EDO in humans. This required the
development of a more efficient expression and purification system, which produced a
recombinant protein that is comparable to the native enzyme in terms of enzymatic

activity and substrate specificity. The incorporation of a hexahistidyl tag, in place of t
GST tag, would provide the same affinity chromatography based purification aid.
Because the 6His tag is much smaller, it would not need to be removed, therefore
overcoming the problems of degradation and low activity of the GST-fusion protein.
Once an efficient expression and purification system for recombinant hexahistidyl
tagged EDO is developed, the recombinant protein, if comparable to the native, could be
used to elucidate the structure of human EDO.

The specific aims of this research therefore are:
(i) Establish a hexahistidyl tagged expression system for human EDO.
(ii) Develop an efficient purification protocol for the recombinant protein.
(iii) Characterise the recombinant protein and compare it to the native protein.
(iv) Undertake structural studies on EDO.
(v) Develop and characterise mutant IDO proteins to identify residues important in
heme/substrate binding in IDO.
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2. Materials and Methods
2.1 Materials

All chemicals were of analytical grade unless otherwise specified. The composition of
all buffers and solutions are outlined in Appendix I. Ultraviolet (UV) spectra were
recorded using a Shimadzu UV-2401PC UV-Vis spectrophotometer (Shimadzu
Corporation, Japan), with a 1 cm pathlength in quartz cuvettes. Sephadex G-50 and
Ampholine (pH 6-8) were purchased from Pharmacia Biotech. Cellulose phosphate
(PI 1) was obtained from Whatman. Nickel-nitrilotriacetic acid (Ni-NTA) agarose resin
was obtained from Qiagen, Inc. L-Kynurenine, L-tryptophan, 5-hydroxy-L-tryptophan,
D-tryptophan, catalase, hemin, ethylenediaminetetraacetic acid (EDTA), imidazole,
phenylmethylsulfonyl fluoride (PMSF), isopropanyl-(3-D-thiogalactopyranoside (IPTG),
ampicillin, kanamycin and sodium dithionite were obtained from Sigma-Aldrich.
Bovine serum albumin (Fraction V) was obtained from Amersham. All restriction
enzymes and the protease inhibitor cocktail were obtained from Boehringer-Mannheim.
The gene Editor™ reaction kit was obtained from Promega Corporation and Big Dye
Terminator was obtained from PE Biosystems.

The monoclonal antibody used was raised against native EDO purified from human
placenta, as previously described [20], which recognises an N'-terminal epitope. A
polyclonal antibody was also raised against purified recombinant hexahistidyl tagged
human EDO (6HisEDO), as described [95].
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2.2 Clonins and expression of human IDO

2.2.1 Bacterial strains and plasmids

E. coli strains used in 6HisEDO expression studies were Ml 5 (Qiagen), 876 (R.
Brownlie), EC538 (J. McCarthy), KS476 (J.E.G. Beckwith and K. Straunch) and YA21
[122].

Plasmid pCR2.1™ and the TA cloning kit were obtained from Invitrogen. The 6His

expression plasmid pQE9 and the repressor plasmid pREP4 were obtained from Qiage
The expression plasmid pGEX-IAT-EDO, which carries a human EDO cDNA [42], was a
gift from Dr. S. Tone (Department of Biochemistry, Wakayama Medical College,
27 Kyubancho, Wakayama 640, Japan)

2.2.2 Construction of the 6HisIDO expression plasmid

The human EDO cDNA was amplified by polymerase chain reaction (PCR) from
pGEX-RT-EDO using primers (5'-GGGTCGACATGGCACACGCTATGGAAAAC3') and (3'-AGGGAAAACTTCCTTCCAATTCAGCTGGG-5') containing Sail
restriction sites (underlined). Primers were commercially synthesised by Auspep
(Melbourne, Australia). The amplified EDO cDNA was cloned into pCR2.1™ using a

TA cloning kit and DNA sequenced to check for the absence of Taq errors. The DNA
was digested with Sail and ligated in the expression vector pQE9.
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2.2.3 Transformation ofE. coli
2.2.3.1 Preparation of electro-competent cells

Routinely, cells were transformed using electroporation. To prepare electro-competent
cells, Luria-Bertani (LB) broth (200 mL) was inoculated with a single colony and

grown to A6oo = 0.5-1. The flasks were briefly chilled and then the cells were harvest
by centrifugation (Beckman JCM2, JA10 rotor, 4000 g, 15 min, 4°C). The supernatant
was removed and the cells were resuspended in cold sterile MilliQ (MQ) H20 (200 mL)
and re-centrifuged. This was repeated with 100 mL of MQ H20 and then with glycerol
(10% w/v) in MQ H2O (4 mL). The cells were resuspended in the aqueous glycerol,
aliquoted into 40 uL samples and stored at -80°C.

2.2.3.2 Electro-transformation ofE. coli

Competent cells (40 uL) were thawed slowly on ice and 1-2 uL of DNA was added.
The suspension was mixed gently and placed in a chilled micro-cuvette (2 mm path
length). The suspension was then electroporated using a Bio-Rad Gene Pulser, set with

a capacity of 25 F, resistance of 200 Q and pulse of 2.5kV, resulting in 12.5 kV/em w
a time constant of less than 5.

SOC media (1 mL) was added to the suspension and the mixture was transferred to a

sterile tube and incubated with shaking (37°C, 1 h). Various volumes were then plated
onto LB plates containing 100 ug/mL ampicillin and 50 ug/mL kanamycin, selecting
for bacterial colonies containing both pREP4 and pQE9-EDO.
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2.2.4 Expression ofE. coliEC538 (pREP4, pQE9-IDO)

E. coli strains were routinely grown at 37°C in LB medium containing ampicillin
(100 ug/mL) and kanamycin (50 ug/mL). All liquid cultures were agitated during
incubation in an orbital-shaking incubator. A single colony of EC538 (pREP4, pQE9EDO) was used to inoculate L B media that was then cultured overnight. Routinely, for
small (100 m L ) and large (1 L ) cultures, samples were inoculated with 1/20 or 1/10
volume of starter culture, respectively. Cultures were grown to a density of 0.6 O D at
600 nm. IPTG (200 m M ) , hemin (3.5 m M in 10 m M N a O H ) and P M S F (200 m M in
isopropanol) were then added at a final concentration of 10 u M , 7 u M and 1 m M ,
respectively. The cultures were then shaken for a further 3 h.

EDTA (500 mM, pH 8.0), was then added to a final concentration of 1 mM and the cells
were pelleted by centrifugation (Beckman JC-M2, JA10 rotor, 3,600 g, 20 min, 4°C).
The pellet from a 1 L culture was resuspended in 10 m L of ice-cold phosphate buffered
saline (PBS) containing P M S F (1 m M ) and E D T A (1 m M ) and centrifuged at 27,000 g
(JA20 rotor) for 15 min at 4°C. The pellet was stored at -20°C for up to 2 months.

2.3 Purification of6HisIDO
2.3.1 Lysing ofE. coli cells

Potassium phosphate buffer (KPB pH 6.5), containing 1 mM PMSF was used in the
following experiments. All procedures were conducted at 0-4°C unless otherwise
stated. The pellet from 2 L of bacterial culture, obtained as described above, was
suspended in 20 m L of P B S containing Complete" inhibitor cocktail, sonicated on ice
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with a Branson Sonifier 250 for 4 min at maximum power and centrifuged (Beckman
JCM2, JA20 rotor, 27,000 g, 15 min).

2.3.2 Cation exchange chromatography

Phosphocellulose (PI 1) resin was activated as per manufacturer's instructions. Bri

the dry resin was stirred in 25 volumes of NaOH (0.5 M) and left for 5 mins. When th

resin had settled, the supernatant was decanted off and the resin washed in distill

water (dH20) until the supernatant was less than pH 11. Resin was then stirred in 2
volumes of HC1 (0.5 M) and left for 5 min. The supernatant was decanted off and the
resin washed with H2O until a pH of greater than 3 was reached. Activated resin was
stored at 4°C in KPB (500 mM) for up to 3 months and was equilibrated with KPB
(50 mM, pH 6.5) prior to use.

The crude supernatant from lysed EC538 (pREP4, pQE9-BDO) cells was applied to a

phosphocellulose (Pll) column specification (0 ) of 2.5 x 4 cm, equilibrated with K
(50 mM). After washing with 50 mM KPB (150 mL) and 100 mM KPB (100 mL),
6HisEDO was eluted with a linear gradient of KPB (100-500 mM, 100 mL of each), at a
flow rate oOO mL/h. Fractions that had an absorbance ratio of 406 nm to 280 nm >0.7
were pooled. Imidazole and glycerol were then added to a final concentration of 10
and 10% (v/v), respectively.
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2.3.3 Affinity chromatography

The basal buffer used for affinity chromatography consisted of KPB (250 mM, pH 6.5),
glycerol (10% v/v) and PMSF (1 mM) with varying concentrations of imidazole
(10-250 mM)

Ni-NTA agarose resin was washed with Milli Q (MQH2O) and equilibrated with basal
buffer containing 10 mM imidazole. The pooled fractions from the phosphocellulose
column were applied to a Ni-NTA agarose column (0 2.5 x 3 cm). After washing with
10 mM imidazole buffer (100 mL) and 50 mM imidazole buffer (100 mL), 6HisEDO
was eluted on a linear imidazole gradient (50-250 mM imidazole, 100 mL each),
monitored by absorbance at 280 and 406 nm. The samples containing high 280 and 406
nm absorbances were pooled.

2.3.4 Concentration of protein

Various membrane concentration systems were used to concentrate protein. During
6HisEDO studies, larger volumes were initially concentrated using Centriflo CF25A
membrane cones (Amicon). Smaller volumes were concentrated using Centricon-100 ™
microconcentrators (Amicon). Prior to use membranes were washed with MQH20, the
protein solution was then added and centrifuged (1000 g, 4°C) using a Beckman
Allegra™ centrifuge and an F0850 rotor.
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For the mutagenesis studies, proteins were concentrated using Ultrafree®-15 centrifugal

filter devices (Millipore), at 2,000 g and 4°C, until the desired volume was obtained.
After concentration, purified 6HisIDO was exchanged into Tris-HCl (50 mM, pH 7.4)
containing EDTA (1 mM) and 40% glycerol and stored at -20°C.

2.4 Characterisation of 6HisIDO and 6HisIDO mutants

2.4.1 IDO activity assay

EDO activity was determined as described by Takikawa et al. [20] with a minor
modification. In brief, the standard reaction mixture (0.5 mL) contained KPB (50 mM,
pH 6.5), ascorbic acid (20 mM, neutralised with NaOH), catalase (200 ug/mL),
methylene blue (10 uM), L-tryptophan (400 uM) and EDO. The reaction was carried out
at 37°C for 10-60 min and was stopped by the addition of trichloroacetic acid (100 uL
of 30% w/v). After heating at 65°C for 15 min, the reaction mixtures were centrifuged

at 6,000 g for 5 min. The supernatant (125 uL) was transferred into a well of a 96 we
microplate and mixed with 2% (w/v) p-dimethylaminobenzaldehyde (125 uL) in acetic
acid. The yellow pigment derived by reaction of /7-dimethylaminobenzaldehyde
(Ehrlich's reagent) with kynurenine was measured at 480 nm using a SPECTRAmax
250 micro plate reader (Molecular Devices, Sunnyvale, CA). L-Kynurenine (1-100 uM)
was used as the standard.
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2.4.2 Protein

determination

Protein concentration was determined using Bio-rad dye reagent concentrate, diluted
1 in 5 with MQH20. The coloured product was measured at 595 nm using the
SPECTRAmax plate reader, as above. BSA (0-1 mg/mL) was used as the standard.

2.4.3 Heme content determination

The heme content of protein was determined by the alkaline pyridine hemochrome
method [123] with horse myoglobin as a standard. Briefly, to the heme protein
(0.2 mg/mL, 366 uL), pyridine (130 uL) and NaOH (10 M, 3.5 uL) were added and the
mixture was bubbled with argon gas (4 min). This solution was then reduced by the

addition of sodium diothionite, until a visible colour change occurred. The 540 nm a
556 nm absorbances were determined and the 540:556 ratio obtained. Myoglobin was

used as the standard with its 540:556 nm ratio representative of a heme protein wit
heme group per molecule of protein. The 540:560 ratio for the sample protein was
compared to the myoglobin ratio and the percentage heme content was determined.

2.4.4 Isoelectric focusing

Purified enzyme sample was concentrated to about 5 mL and the solvent was changed
to a 1 mM sucrose buffer. The enzyme was subjected to isoelectric focusing in a LKB
8101 column (110 mL) in 1% (w/v) Pharmalyte (pH 6.7-7.7) with a stepwise sucrose
gradient. The focussing was carried out at 500V for 48 h.
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2.4.5 Sodium

dodecyl sulphate polyacrylamide gel electrophoresis

(SDS-PAGE)

Routinely sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE)
[124] was conducted to visualise protein. For whole cell lysates, pelleted cells were
resuspended in PBS and then an equal volume of 2x cracking buffer was added. The
samples were boiled for 10 min and if necessary, briefly centrifuged to remove any
solids.

Samples were separated through a 12% polyacrylamide gel, with a 4% stacking gel.
Protein samples were electrophoresed for a period of 1.5-2 h in SDS running buffer
using a Bio-rad Protean E gel system, with a voltage of 120 V. Gels were immersed in
rapid Coomassie blue stain, heated for 1 min on high power in a microwave oven and
incubated at room temperature for 1 h, with shaking. Gels were destained by repeating
the above heating/shaking protocol, using rapid destain and were then transferred to
final destain, which contained 4% glycerol to reduce cracking of gels upon drying.
Stained gels were imaged using the Novaline Gel Documentation System.

2.4.6 Western blot analysis

Following SDS-PAGE, proteins were transferred to a PVDF membrane in pre-chilled
Western transfer buffer (15 V, overnight). The membrane was blocked with 5% (w/v)
skim milk powder in PBS (20 mL) for 1 h with gentle shaking at room temperature.
The membrane was then washed with PBS (3x, 10 min) and the first antibody was
added (1/2000 dilution, 10 mL) and incubated for 1 h. The membrane was again
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washed with P B S (3x, 10 min) and the second antibody was added (1/1000, 10 m L ) .
The membrane was washed with PBS (3x, 10 min) then developed using horseradish
peroxidase substrate solution. The membrane was then washed with MQH20.

2.4.7 Mass spectrometry

Electrospray ionisation (ESI) mass spectrometry of protein was performed on a VG
Quattro mass spectrometer (VG Biotech, Altrincham, UK). Samples were desalted with
a mini-column of Sephadex G-50 and injected at -10 pmol/uL in Milli-Q™ water. ESI

conditions were achieved with a nitrogen bath gas flow of 350 L/h and nebulising gas
flow to the probe at a rate of 10 L/h. The skimmer potential was set at 25-35 V,

capillary tip potential at 3.2 kV and the resolution to 1.0 (peak width at half peak

height). The mass was scanned at a rate of 1 sec per 100 m/z, and data from 10-20 sc
were summed to obtain representative spectra. The ESI mass spectra of proteins were
transformed from an m/z scale to a mass scale via mutli-channel maximum entropy
analysis.

2.4.8 Circular dichroism spectroscopy

Circular Dichroism (CD) spectra were recorded on a JASCO, J-810 spectropolarimeter,
(JASCO Corporation, Japan) with 1 cm pathlength quartz cuvettes. Sensitivity was
100 mdeg, and the scanning speed was 50 nm/min, for an accumulation of 5 scans.
Further analysis of CD data was undertaken using the K2D program [125, 126] that is
located at www.embl-heidelberg.de/~andrade/k2d/.
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2.5 Site directed mutagenesis

Site directed mutagenesis was carried out as per manufacturer's instructions. Figure 2.1
represents the mutagenesis protocol.
6HisIDO

Amp1"

Refer to section 2.5.2 a n d 2.5.3
1. Alkaline denature dsDNA template
PQE9-IDO (2 5.2)
2. Anneal mutagenic primer and bottom
selection primer (2.5.3)

6HisIDO mutant primer
Refer to section 2.5.4
3. Synthesise mutant strand withT4 D N A
polymerase and T4 D N A ligase

r

A m p bottom strand-i.
selection primer

Refer to section 2.5.5

1

4. Transform plasmid DNA into E.coli
B M H 71-18 mutS cells

5. Grow in presence of
antibiotic selection mix
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10. D N A sequence potential mutants (2.3.4)

6HisIDO
Mutant
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r

~ \
pQE9-mutant T D O

pREP4

E. coli EC538 (pREP4, pQE9-mutantIDO)
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Figure 2.1 Site-directed mutagenesis protocol. The site-directed mutagenesis protocol using the
GeneEditor™ in vitro site-directed mutagenesis system. The purified double stranded pQE9-IDO D N A
was alkaline denatured and the mutagenic and selection primers were annealed. T 4 Ligase and
polymerase were then added and the mutant strand synthesised. The plasmid D N A was then transformed
into E. coli B M H 7 1 - 1 8 mutS cells and grown in the presence of the selection antibiotic mix. Only cells
containing plasmid D N A that had undergone the selection mutation grew. The plasmid D N A was then
isolated and transformed into E. coli J M 1 0 9 cells and clones containing the desired site-specific mutation
were then identified using D N A sequence analysis. The plasmid D N A containing the desired mutation
was then transformed into E. coli E C 5 3 8 (pREP4). (Figure modified from technical notes, Promega
Corporation).
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2.5.1 Design of mutagenic primers

Primers for mutagenesis were designed as per manufacturer's instructions. The initial

primer length was 21 bases long, but this increased to 42 bases for some mutations. T
sequence details on the mutagenic primers are outlined in Table 5.1.

Primers were commercially synthesised by Sigma Genosys (Castle Hill, Australia).
Mutagenic primers were designed to anneal to the top strand, therefore the bottom
strand selection primer was used to create the selection mutation to the ampicillin
resistance gene.

2.5.2 DNA template denaturation

Routinely, sufficient dsDNA was denatured to allow for 10 mutagenic reactions. To
approximately 2 ug of template dsDNA, 2 M NaOH, 2 mM EDTA (2 uL) and MQH20
were added to a total volume of 20 uL. This mixture was incubated at room
temperature for 5 min, then ammonium acetate (2 M, pH 4.6, 2 uL) and ethanol (100%,

75 \xL) were added, prior to incubation at -70°C for 30 min. The DNA was precipitated

at 15,000 g for 15 min at 4°C. The supernatant was removed and the pellet resuspended
in ethanol (70%, 200 uL) and re-eentrifuged. The supernatant was again removed and
the DNA pellet was air dried before being resuspended in 100 uL of TE buffer.
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2.5.3 Hybridisation

Reaction

To the denatured template DNA (10 \\L, 0.05 pmol), bottom selection oligonucleotide
(0.25 pmol), mutagenic oligonucleotide (1.25 pmol), annealing buffer (2 \\L) and
enough sterile MQ H20 to make a final volume of 20 uL were added. The DNA was

then annealed by heating to a temperature of 75°C for 5 min and then allowed to slo
cool to 37°C at approximately 1.5°C per min.

2.5.4 Polymerisation and ligation of mutant strand

After the annealing reaction reached 37°C, sterile MQH20 (5 uL), synthesis buffer
(lOx, 3 uL), T4 DNA polymerase (5-10 units) and T4 DNA ligase (1-3 units) were

added, resulting in a final volume of 30 \xL. The reaction mixture was then incubat
37°C for 90 min.

2.5.5 Transformation ofE. coli BMH71-18 mutS and JM109 cells

DNA (1.5 uL) was transformed into E. coli BMH 71-18 mutS cells (100 uL) and after
culturing in LB (1 mL) without antibiotics for 1 h at 37°C, overnight cultures were
prepared by the addition of LB (4 mL) containing GeneEditor™ antibiotic selection
(50 fiL). DNA was then purified from the overnight culture using Qiagen Spin

extraction columns and transformed into competent JM109 cells using electrophoratio
SOC media (1 mL) was added to the cells, which were then incubated at 37°C for 1 h
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with shaking. The mixture was aliquoted and plated onto L B agar plates containing
GeneEditor™ antibiotic selection mix (75 uL/mL) and ampicillin (125 ug/mL), then
incubated at 37°C overnight. Single colonies were selected and screened for mutations.
The extracted DNA was first screened by restriction enzyme disgestion with Sail to
check for the release of a 1.2 kDa fragment (IDO) and was then sequenced (as outlined
in section 2.6.2 and 2.6.4 below).

2.6 Other molecular techniques
2.6.1 Plasmid DNA extraction

Larger scale extraction of plasmid DNA was performed using Plasmid Midi-Prep kit
(Qiagen) as per manufacturer's instructions. Briefly, 100 mL of bacterial culture was
grown overnight to an absorbance at 600 nm of 1-1.5 and the cells were harvested by
centrifugation at 6,000 g (15 min, 4°C). Following alkaline lysis of the host cells,
samples were loaded onto a DNA binding column. This column was washed several
times prior to eluting the DNA. The DNA pellet was washed briefly with ethanol
(70%) then air-dried before resuspension in TE buffer. Using the same procedure,
small-scale extraction of plasmid DNA was performed with a Plasmid Spin-Prep kit
(Qiagen).

2.6.2 Restriction enzyme digestion

Restriction enzyme digestions were routinely set up using DNA isolated with Qiagen
spin column extractions with Sail to confirm the presence of the IDO gene. To DNA
(5 uL) restriction enzyme (1 uL), buffer (2 uL) and sterile MQH20 (12 uL) was added.
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Reaction mixtures were incubated at 37°C for 2-4 h, then 10 uL was loaded onto an
agarose gel.

2.6.3 Agarose electrophoresis

Agarose gels were routinely 0.85% agarose in lx TAE buffer. DNA was loaded with

bromophenol blue/glycerol loading dye and gels were run in lx TAE at 74 V in a MiniSub Cell (Bio-Rad). DNA was visualised by staining with ethidium bromide for
15 min, followed by illumination under UV light. Stained gels were imaged using the
Novaline Gel Documentation System. Typically lambda bacteriophage DNA digested

with Hind IE restriction enzyme or 1 kb ladder were used as molecular weight markers
to determine the size of DNA fragments.

2.6.4 DNA sequence analysis

The primers for the sequencing of the pQE9-IDO mutants are outlined in Table 2.1.
The IDO Down and IDO Up primers were designed to sequence from the middle of the
IDO gene, and the pQE9 Type HI/TV and pQE9 Reverse primers were based on the
pQE9 plasmid, as recommended by Qiagen. The primer locations are outlined in Figure

2.2. Primers were obtained from Sigma Genosys (Castle Hill, Australia). Primers were

resuspended to a concentration of 80 pmol/uL in TE buffer and then to a concentratio
of 1.6 pmol/uL with sterile MQH20. Routinely, template DNA was prepared using
Spin Prep Columns (Qiagen) and resuspended in MQH20 (40 uL) that contained
approximately 400 ng of DNA.
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Table 2.1 D N A sequencing primers. Sequence of primers used for the sequencing of pQE9-ID0
mutants. IDO D o w n and IDO U p were based on the IDO D N A and pQE9 Type IILTV and pQE9 Reverse
were based on the pQE9 plasmid as recommended by Qiagen.

Primer

_____

Sequence

EDO Down 5' AAGTGTTTCACCAAATCCACG 3'
IDO Up 5' AAGGGCTTTCTCCAAGCAAGA3'
pQE9 Type m/IV 5' CGGATAACAATTTCACACAG 3'
pQE9 Reverse 5' GTTCTGAGGTCATTACTGG 3'

Human IDO
0

I

1000

I

I

I

I

I

2000

I

I

I

I

I

3000

I

I

I

I

I

pQE9 Type III/IV ^ pQE9 Reverse

IDO Up
IDO Down

Figure 2.2 Localisation of D N A sequencing primers. Schematic representation of the localisation of
the primers used for D N A sequence analysis for pQE9-IDO.

Sequencing reactions consisted of primer (2 \\L of 1.6 pmol/|jL), template DNA
(400 ng), Big Dye ready reaction mix (4 uL) and sterile MQH20 to make a final volume

of 10 uL. Reaction mixtures were cycled with denaturing (96 °C for 10 sec), anneali
(50°C for 5 sec) and polymerisation (60 ° C for 4 min), for a total of 25 cycles.

The sequencing reaction (10 uL) was precipitated by the addition of sodium acetate
(3 M, pH 4.6, 2 uL), ethanol (95%, 50 uL) and incubated on ice for 10 min. The
sample was then centrifuged (10,000 g, 20 min) and the pellet was resuspended in
ethanol (70%, 250 uL), re-centrifuged and the supernatant removed. The pellet was

then air dried for 1-2 h. The pellet was resuspended in formamide loading dye (6 uL
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and the sample was heated (90°C, 2 min) to promote denaturation and placed on ice
prior to loading. A volume of 2 uL was loaded onto the DNA sequence gel.

2.6.4.1 DNA sequence gel electrophoresis

Polyacrylamide sequencing gels were made using a 4% acrylamide (19:1 acrylamide:
bis-acrylamide) buffered with IX TBE and containing 6 M urea. The gel solution was
exposed to amberlite ion exchange resin, filtered through a 0.2 uM cellulose nitrate
filter and degassed for 10 min prior to polymerisation with ammonium persulfate and
N,N,N',N'-tetra-methylethylenediamine (TEMED) and injected into an ABI casting

apparatus containing 48 cm glass plates. After a curing time of 2 h, the gel was prefor 1 h until the gel temperature was maintained at a constant 48 °C. Samples (2 uL)
were loaded onto the gel with the aid of a sharktooth comb. The gel was then run for
10 h on an ABI 377 DNA sequencer at a constant 37 W (-2350 V, 16 mA).

2.6.5 Amino acid sequence analysis

Amino acid sequence of 6HisIDO was determined at the Australian National
University, Canberra by Dr Dennis Shaw. N-terminal sequencing was undertaken using
the Edman method with a Perkin-Elmer Applied Biosystems 494 protein sequencer.
Sequencing of the C-terminus of the protein was carried out by the method of Boyd
et al. [127] with a Perkin-Elmer Applied Biosystems 492C protein sequencer.
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3. Cloning, expression and purification of
human IDO

As previously stated, to facilitate the elucidation of structural features of EDO, a ne
expression system for human EDO that produced a functional enzyme was required.
The 6His expression system was chosen as it incorporates an affinity tag, which aids
protein purification. This 6His tag in most cases does not need to be removed prior to

characterisation, whilst maintaining a functional protein [48, 49]. The 6His expression
system uses the commercially available pQE9 expression vector and Ni-NTA agarose,
affinity chromatography resin (Qiagen). This chapter reports the establishment of the
6His tagged expression plasmid for human IDO and the optimisation of this expression
system. The protocol development for the purification of bacterially expressed
recombinant human IDO will also be shown.

3.1 Clonins of the human IDO 2ene into the expression vector
pQE9

The expression plasmid pQE9-IDO was constructed by Mr. D. Skylas, as described
below. Human EDO cDNA was amplified by PCR from pGEX-lAT-IDO [42], using

primers containing Sail restriction enzyme sites (refer to section 2.1.2). The expressio
plasmid pGEX-lAT-IDO contains an IPTG inducible tac promotor and expresses
human IDO as a GST fusion protein. The PCR amplified IDO cDNA was cloned into
the plasmid pCR2.1™, using a TA cloning kit and sequenced to check for the absence
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of P C R amplification Taq errors. The D N A was digested with Sail, ligated into the
expression vector pQE9 and then transformed into E. coli strains (pREP4).
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Figure 3.1 Plasmid pQE9-IDO. (A) Diagrammatic representation of the expression plasmid pQE9-IDO,
which contains the human IDO c D N A gene (open box) [42] cloned into the vector pQE9 (Qiagen), which
contains a hexahistidyl tag (filled box), bacteriophage T5 promoter upstream of two lacO operators (filled
arrow), p-lactamase gene (bla, open box) and E. coli origin of replication (open box). The orientation of
open reading frames is indicated by thin arrows. The plasmid is not drawn to scale and only relevant
restriction sites are shown. (B) 0.85% Agarose gel. Lane (1), pQE9; Lane (2) pQE9 cut with Sail, Lane
(3) pQE9-IDO, pREP4 and Lane (4) pQE9-IDO, pREP4 cut with Sail. The sizes of mass markers (kb)
and the bands corresponding to p Q E 9 and IDO (arrows) are indicated.
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Bacterial colonies, containing both pQE9-EDO and pREP4 were isolated on LB agar

plates with antibiotic selection. Clones carrying pQE9-IDO in the correct orientation
were identified by restriction enzyme digestion and DNA sequence analysis of the
extracted plasmid. One such clone was designated plasmid pQE9-IDO (Figure 3.1 A).
Digestion of pQE9-IDO with Sail released a 1.2 kb fragment of IDO cDNA and a
3.5 kb fragment, which corresponded to the vector pQE9 (Figure 3.IB).

3.2 Expression of 6HisIDO in E. coli EC538 (pREP4,
POE9-IDO)

The plasmid pQE9-IDO expressed a recombinant human EDO (6HisIDO) protein in
which a hexahistidyl tag was attached to full size DDO (403 amino acids), at the
N-terminus, with a spacer sequence of four amino acids. The recombinant 6HisIDO was
expected to comprise 417 amino acids, with the N-terminal consisting of
N' -MRGSHHHHHHGSVDJl£4/£4... .-C' (the hexahistidyl tag is underlined and the
human EDO open reading frame is italicised). Protein expression was under

transcriptional control of the phage T5 promoter and lac operator, with transcription
capable of being repressed by the lac repressor protein produced by plasmid pREP4.

Expression of 6HislDO protein was achieved by the addition of IPTG to cultures, which

binds to the lac repressor protein and inactivates it. Crude lysates of E. coli. EC538
(pREP4, pQE9) and EC538 (pREP4, pQE9-EDO) were examined by SDS-PAGE
(Figure 3.2). The presence of an additional band of approximately 45 kDa was
observed in the lane containing EC538 (pREP4, pQE9-EDO). This was confirmed to be
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human I D O by Western blot analysis using a monoclonal antibody raised against the
native human placental IDO [20] (Figure 3.2).

B
80—

52.5—

21.5 —

Figure 3.2 Expression of 6HisIDO. Lane (1) E. coli. EC538 (pREP4, pQE9); Lane (2) E. coli. EC538
(pREP4, pQE9-IDO), both were induced with IPTG (1 m M ) for 3 h. (A) Coomassie brillant blue stained
1 2 % acrylamide S D S - P A G E gel. (B) Western blot analysis detected using a monoclonal antibody raised
against placental human IDO. The sizes of molecular mass markers (in kilodaltons) and the presence of
recombinant human I D O (arrows) are indicated.

3.2.1 Bacterial strain selection for optimal 6HisID0

expression

To find the most suitable E. coli strain for expression of 6HisIDO, the level of protein
expression was measured in five E. coli strains (EC538, YA21, M15, KS474 and 876)
carrying pREP4, which were transformed with pQE9-EDO. To investigate expression

efficiency, the IDO activity of a 1 mL sample from each host cell was examined after
induction by IPTG (1 mM), for 4 h, in a 20 mL culture.
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IDO activity was detected in the crude extracts of each strains (Figure 3.3), indicati
that all transformed cells produced a functional enzyme. The strain with the highest
activity was EC538 (pREP4, pQE9-IDO), with 4.3 nmoles of kynurenine produced per
hour per mg of enzyme. EC538 cells were therefore selected as the host strain for the
subsequent expression and purification of 6HisIDO.

5
o

4
3
2

0

11

S

0
a

itt
KS876

KS474

M15

YA21

EC538

E. coli H o s t Strain

Figure 3.3 6HisIDO expression in E. coli strains. IDO activity of whole cell lysate of E. coli strains
transformed with pREP4 and pQE9-IDO. Cells were induced with IPTG (1 m M ) for 4 h. Strams were
sampled and measured in duplicate.

3.2.2 IPTG

concentration for optimal 6HisIDO

expression

The optimal concentration of I P T G required for expression of 6HisIDO by E C 5 3 8
(pREP4, pQE9-IDO) cells was determined. Initial experiments were conducted with
1 mM IPTG, as recommended by Qiagen. To investigate whether this concentration
was optimal, IDO activity was determined for cultures induced with IPTG
concentrations ranging from 1 uM to 10 mM. As shown in Figure 3.4, 6HisIDO
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induction was dependent on the concentration of IPTG and maximal induction was

observed at approximately 10 yM IPTG. This concentration was used in all sub
expression studies.
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Figure 3.4 I P T G dependency of 6HisIDO expression. IPTG dependency of 6HisIDO expression in
E coli EC538 (pREP4, pQE9-IDO) cells. Cultures were grown for 3 h with the indicated IPTG
concentrations, in a 20 m L culture. I D O activity in each bacterial crude extract was determined after
sonication. Strains were sampled and measured in duplicate.

3.2.3 length of induction for optimal 6HisIDO expression

Prior to expressing large quantities of 6HisDDO for protein purification, the

length of time for EC538 (pREP4, pQE9-EDO) growth, post-induction, was determ
This was examined by monitoring the growth of the culture (absorbance at 600

by analysing the amount of 6HisEDO in the crude lysate by SDS-PAGE and Wester
blot analysis.
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Figure 3.5 Induction of EC538 (pREP4, p Q E 9 ) and EC538 (pREP4, pQE9-IDO). (A) EC538
(pREP4) cells containing either p Q E 9 or pQE9-IDO. Growth curve monitored absorbance at 600 nm.
A n arrow indicates the time of induction with IPTG (10 u M ) (B) and (D) EC538 (pREP4, pQE9); (C)
and (E) EC538 (pREP4, pQE9-IDO). (B) and (C) Coomassie bnllant blue stained 1 2 % acrylamide
SDS-PAGE gel. Lane (1) 1 h post induction; Lane (2) 2 h post induction; Lane (3) 3 h post induction;
Lane (4) 4 h post induction, Lane (5) 5 h post induction. (D) and (E) Western blot analysis of the same
samples as above, using a monoclonal antibody raised against human placental IDO. The sizes of
molecular mass markers (kDa) and the presence of recombinant human IDO (arrows) are indicated.
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As shown in Figure 3.5A the level of EC538 (pREP4, pQE9-EDO) cell growth plateaued
at approximately 3 h post-induction. The level of IDO expression was concurrently
measured, with samples taken at hourly time points and examined by SDS-PAGE and
Western blot analysis against a monoclonal antibody raised to human placental IDO

[20] (see Figure 3.5B-D). As with cell growth, the level of IDO expression appeared to
plateau by 3 h post-induction. All subsequent expression work was therefore conducted
with EC538 (pREP4, pQE9-BDO), which was induced with 10 uM IPTG, for a period of
3 h, before cells were harvested.

3.3. Purification of6HisIDO
3.3.1 lysis ofEC538 (pREP4, pQE9-IDO) cells

Cell lysis was initially attempted using a lysis buffer [43] containing Triton-X 100
(1% w/v), lysozyme (1 mg/mL), catalase (0.05 mg/mL), NaCl (0.3 M), imidazole
(10 mM), p-mercaptoethanol (2 mM) and DNase. The 6HisIDO obtained, however, had
low activity and a low yield. The effect of various components of the lysis buffer on

IDO activity was therefore investigated, by measuring the activity of partially purif
EDO in the presence of Triton X-100, Tween 20 or (3-mercaptoethanol (Figure 3.6).

Detergents and p-mercaptoethanol greatly reduced IDO activity, even at low
concentration of 0.1% (w/v) and 0.1 mM, respectively. Both Triton-X 100 and Tween
20 inhibited approximately 80% of EDO activity, whilst (3-mercaptoethanol reduced

activity by over 40%. Given that the lysis buffer components reduced EDO activity and
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the protein yield was low with this method of cell lysis, sonication was trialed to lyse
the cells.

-•-Triton-X 100
-*— Tween 20
-•—B-Mercaptoethanol (mM)
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Figure 3.6 Effect of detergents and P-mercaptoethanol on I D O activity. The effects of various
components of the lysis buffer were investigated after low yields and low activity was observed in the
protein purification. This figure depicts the % inhibition of IDO specific activity (nmoles of
kynurenine/h/mg of protein) that the indicated concentrations had on partially purified 6HisIDO.

Sonication was conducted on ice in the presence of Complete™ inhibitor cocktail and
EDTA, to help prevent protein degradation. IDO activity plateaued after approximately
4 min of sonication at maximum power. Both yield and activity of enzyme were
increased with sonication, when compared to other methods of lysis. Sonication was
therefore employed for subsequent work.

3.3.2 Cation exchange chromatography

N i - N T A affinity chromatography is a powerful purification tool for hexahistidyl tagged
recombinant proteins. An initial cation exchange chromatography step to remove
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EDTA needed to be incorporated into the purification protocol. EDTA was added
during cell storage and lysis to inhibit proteolysis. Its removal prior to Ni-NTA
chromatography was necessary, as EDTA is a metal chelator and would chelate the
nickel ions and remove them from the NTA agarose backbone.

Cation

exchange

chromatography

was

undertaken

using

Whatman

Pll

phosphocellulose ion exchange resin, with a potassium phosphate buffer (KPB) system,

as outlined in Section 2.3.2. After sonication, the crude extract was centrifuged and t
supernatant was loaded onto the phosphocellulose column, which had been equilibrated
with 50 mM KPB. The column was then washed with 50 and 100 mM KPB prior to
elution. 6HisIDO was eluted from the column by a linear KPB gradient of
100-500 mM. A typical elution profile (Figure 3.7) shows that 6HisIDO was eluted at
around 200 mM KPB. This resulted in a 27.3-fold purification and the isolated protein
had a specific activity of 139 nmoles kynurenine/h/mg protein, with L-tryptophan as a
substrate (Table 3.1).
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Figure 3.7 Cation exchange chromatography elution profile.
Typical cation exchange
chromatography elution profile. Column consisted of Whatman Pll phosphocellulose resin. Crude
supernatant containing 6HisIDO was applied and eluted on a linear potassium phosphate buffer (KPB)
gradient; the green line represents theoretical gradient. The eluted fractions were monitored by
absorbance at 280 n m (red line) and 406 n m (blue line).
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3.3.3 Affinity chromatography

Ni-NTA resin is capable of binding 5-10 mg of hexahistidyl tagged protein per mL of
resin (Qiagen, Australia). To determine the optimal amount of Ni-NTA resin for
6HisIDO purification, varying amounts of resin were combined with crude lysate, until
the supernatant had no activity, indicating that all hexahistidyl tagged protein was
bound to the resin. It was found that for each mL of supernatant with an absorbance
(406:280 nm) ratio equivalent to 1, approximately 0.5 mL of Ni-NTA resin was
required.
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Figure 3.8 Affinity chromatography elution profile. Typical elution profile of affinity chromatography
(Ni-NTA resin, Qiagen). A potassium phosphate buffer system (250 m M , p H 6.5), containing 1 0 %
glycerol (v/v) was used and oTIisIDO was eluted by a linear imidazole gradient, (theoretical gradient
represented by the green line). The eluted fractions were monitored by absorbance at 280 nm (red line)
and 406 nm (blue line).

T o the pooled fractions from the cation exchange column, glycerol ( 1 0 % v/v) and
imidazole (10 mM) were added. This was then loaded onto a Ni-NTA resin equilibrated
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with a 10 mM imidazole buffer. After washing with 10 and 50 mM imidazole buffer,
6HisIDO was eluted from the Ni-NTA column using a linear imidazole gradient

(50-250 mM), as described in Section 2.3.3. A typical elution profile is shown in Fig
3.8. The affinity chromatography resulted in a 29.3-fold purification from the crude
lysate, with a specific activity of 149 nmoles kynurenine/min/mg protein, with
L-tryptophan as the substrate.

3.3.4 Degradation of6HisIDO

Although initial purified 6HisEDO samples appeared homogenous by SDS-PAGE

analysis, ESI mass spectrometry demonstrated that they consisted of two proteins with
molecular sizes of 46,976 and 45,437 Da, as shown in Figure 3.9. To determine the
nature of the two proteins, amino acid sequencing was conducted by Dr D. Shaw,
Australian National University.

The N-terminal sequencing of the preparation showed it contained only one amino acid
sequence Formyl-MRG-SFIHHHHH, however, two C-terminal sequences were detected
upon analysis, these being:
A: MNFLKTVASTTEKSLLKEG-COOH
B: MNFLK-COOH
This finding confirmed that the larger protein, A, was the expected intact 6HisEDO
protein. Whereas the smaller protein, B, was generated by a tryptic-like cleavage of
intact recombinant EDO after Lys403 and was thus lacking 14 amino acids (underlined)
from the C-terminus of full length human IDO. The theoretical molecular weights of

-66-

Chapter 3: Cloning, expression and purification of human

IDO

(A) 46,976 D a and (B) 45,437 D a based on the deduced primary sequence, are
consistent with those determined by mass spectrometric analysis.

To prevent cleavage by an endogenous trypsin-like protease present in E. coli host ce

PMSF (lmM), a serine protease inhibitor, was added to the culture during the induction
phase. The addition of PMSF did not affect IDO expression (see Figure 3.10). PMSF

was also added to all buffers used for purification. EDTA was added to the cultures a

the end of induction, to further reduce protein degradation during harvesting and sto

of the cells. The truncated protein was undetectable by mass spectrometric analysis in
the samples prepared in this manner (see Figure 3.9).
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Figure 3.9 Electrospray ionisation (ESI) mass spectrometry of 6HisIDO. The upper
panel (A) 6HisEDO sample preparation purified in the absence of P M S F ; (B) 6HisIDO
sample preparation purified in the presence of P M S F (1 m M ) and E D T A (1 m M ) .
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3.3.5 Heme content of6HisIDO

The heme (protoporphyrin IX) content of the homogenous 6HisIDO was determined by
the alkaline pyridine hemochrome method [123] using myoglobin as the standard. This
indicated that the heme content of 6HisIDO was low, 0.4 mole per mole of enzyme.
Therefore it was concluded that 60% of the 6HisIDO was apoprotein, i.e. free of heme.

Addition of exogenous heme to the purified protein by collaborators at the Heart
Research Institute (S. Thomas and A Terentis) was unsuccessful, with difficulties
encountered in removal of non-specific bound heme. Hemin (ImM) was therefore
added to the culture during induction. As shown in Figure 3.10, the addition of hemin
during the induction resulted in an increase in specific IDO activity in the crude lysate.
It is worth noting that although the heme content is increased from 0.4 to 0.8 moles per
mole of enzyme, that the activity is increased by only 30%, this indicates that there may
be some mis-folded protein which has incorporated heme, but that is inactive.
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Figure 3.10 Effect of protease inhibitors and hemin on IDO activity. The % IDO activity of crude
cell lysate of
cultures induced in the presence of P M S F (1 m M ) , E D T A (1 m M ) or hemin (7
uM). Control cultures were induced with IPTG (10 uM), and the negative control was not induced.
Specific activity refers of nmoles of kynurenine /h/mg protein, with L-tryptophan as the substrate.
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3.3.6 Optimal conditions for expression and purification of EC538
(pREP4, pQE9-IDO)

As a result of the above findings, the expression and purification protocol was
optimised by the addition of PMSF (1 mM) during the induction phase and to all buffers
used during purification. EDTA (1 mM) was added to the culture media prior to
harvesting and during storage of the cells. This reduced the proteolysis that was
initially observed, which resulted in a C-terminally truncated form of 6HisIDO being
purified. Addition of hemin during the induction phase, increased the heme content of
6HisEDO to 0.8 moles heme per mole of protein.

Table 3.1 shows a summary of the purification of 6HisEDO from the bacterial pellets of
16 L of E. coli EC538 (pRE4, pQE9) culture. The enzyme was purified approximately
30-fold from the crude extract using two chromatography steps, resulting in a single
band on SDS-PAGE (Figure 3.11). Recovery was 56% from the crude extract and yield
was 22.3 mg, corresponding to 1.4 mg of 6HisEDO per litre of culture.

Table 3.1 Purification summary of 6HisIDO. Purification of 6HisIDO from 16 L of culture ofE. coli
(pREP4, pQE9-IDO), using a cation exchange column, followed by an affinity, chromatography step.
*The enzyme activity was determined with L-tryptophan as substrate.

Step

Volume

Total
Protein
(mg)

Total
Activity
Oxmol/h)

Specific
Activity
(/tmol/h/mg
protein)

Yield

(mL)

Crude Extract

180

1161.5

5899

5.1

100

1

Phosphocellulose

110

34.3

4769

139

81

27.3

Ni-NTA

1.2

22.3

3331

149

56

29.3
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Figure 3.11 S D S - P A G E and Western blot analysis of purified 6HisIDO. (A) Coomassie brillant blue
stained 1 2 % acrylamide gel of purified 6HisIDO. (B) Western blot analysis of purified 6HisIDO,
detected using a monoclonal antibody raised against human placental IDO. The sizes of molecular mass
markers (kDa) and the presence of recombinant human IDO (arrows) are indicated.

3.4 Discussion

This chapter describes the development of an efficient system for the expression and

purification of enzymatically active recombinant human IDO. As outlined in

introduction, IDO is widely distributed in humans and is found in the high

the placenta [17]. IDO has been successfully purified from human placental

however, even in this tissue the IDO activity (0.015 umoles kynurenine/hr/

[20] is low, only being about 5% of that of rabbit intestinal EDO [16]. Ad

placental purification system was inefficient, requiring a 10,000-fold pur
and also relied on gaining access to human placentas.
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A common technique for gaining access to large amounts of a specific protein is the
establishment of a recombinant expression system. In 1992 Maeda et al. [42] reported
an expression system for human EDO in E. coli. The expression plasmid,
pGEX-lAT-EDO, expressed a full-length EDO protein with a GST tag. GST tags are

attached to facilitate affinity purification using glutathione-Sepharose beads [44]. Afte
purification the GST tag can, in theory, be cleaved from the protein using site-specific
proteases such as thrombin or blood coagulation factor Xa, which are then separated
from the protein by absorption on glutathione-agarose [44]. The enzyme activity of the
EDO-GST fusion protein however, has been found to be only 20% of that of the native
enzyme and it has proven to be very difficult to enzymatically cleave the GST moiety
without also generating significant fragmentations of EDO [20]. Work carried out in our
laboratory also showed that the enzyme was unstable, losing 70% of activity after
24 h when stored at -20 °C [43]. As such the pGEX-1 XT-EDO expression system, was
not optimal, with the EDO obtained having a lower activity and stability than native
enzyme purified from human placenta. Therefore, a more efficient expression system
needed to be developed to provide large amounts of protein for structural analysis and
to aid in inhibitor design.

Using a hexahistidyl tag would overcome the problems associated with the GST
recombinant expression system, in that the 6His tag is much smaller (0.83 kDa)
compared with the GST tag (26 kDa). Reducing the size of the tag eliminates the need
to cleave it. This should overcome the problem of insufficient tag removal and
degradation encountered during the GST tag cleavage. It has been reported that
protease cleavage of the tag is, in many cases, not necessary for functional tests of the
recombinant hexahistidyl tagged protein [48, 49].
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As with the GST-fusion system of glutathione-Sepharose beads, a powerful affinity
chromatography resin for purifying hexahistidyl tagged proteins has been developed,
i.e. Ni-NTA resin. This resin has a high protein binding capacity and the buffers used

are not restrictive, with the protein eluted in the buffer of choice containing imidazole a
physiological pH. Also the 6His tag can be added to either the N'- or C-terminus [49].
In this case we report the addition of an N' -terminal hexahistidyl tag using the
expression vector pQE9. A C-terminal hexahistidyl construct has previously been
produced, but expressed 2-4 times less efficiently than the N'-terminal construct
(D. Skylas, unpublished results)

The expression vector pQE9-IDO produced a functional enzyme, with optimal
expression achieved in EC538 E. coli strain (pREP4, pQE9-IDO) by the addition of
10 uM IPTG, for a period of 3 h. Purification techniques were used to ensure that
biological activity of the enzyme was retained. Purification under denaturing conditions
would require refolding of the purified protein, which may have resulted in a loss of
enzymatic activity. Since it was intended to perform extensive structural studies on the
recombinant IDO it was important that the native conformation was retained, therefore
the use of denaturing conditions and refolding was not optimal. The purification
protocol developed was based on the use of Ni-NTA affinity chromatography; however,
a cation exchange chromatography step was incorporated to allow for the addition of
EDTA, a metalloprotease inhibitor, to reduce degradation during harvesting, storage and
lysis of cells. All purification steps were also conducted at 4°C to reduce degradation.

The initial chromatography step, although primarily introduced to facilitate the use of
EDTA, resulted in a 27.3-fold protein purification. Upon examination by SDS-PAGE,
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this sample contained only a small number of minor contaminant bands. After elution
from the cation exchange column the protein was susceptible to degradation as the
EDTA had been removed. This required the subsequent affinity chromatography to be
undertaken without delay. Proteins eluted from the cation exchange column were in
KPB buffer, which was also suitable for affinity chromatography. To the collected
protein, a low concentration of imidazole (10 mM) and glycerol (10% v/v) were added
to reduce non-specific interactions.

Upon examination of the purified protein sample, using mass spectrometry, two proteins
were detected. These were analysed by amino acid sequencing, which showed that in
addition full length EDO there was a truncated protein. This truncated protein lacked 14
amino acids from the carboxy terminus. Initial attempts to separate these proteins using
chromatofocussing, however, did not result in a clean separation. Concurrent
experimental attempts to inhibit the degradation by the use of protease inhibitors were
successful, so this methodology was used to attain pure, full-length 6HisEDO. Protease
inhibition involved the addition of PMSF to cultures during the induction phase and to

all buffers during purification, as well as the addition of a protease inhibitor cocktail
during cell lysis. These modifications resulted in the truncated protein being
undetectable by ESI mass spectrometric analysis. The molecular weight of the fulllength protein was 46,967 Da. This was as expected by the addition of 6His (823 Da)
and 8 spacer amino acids (including the expression of formyl methionine), which added
820 Da to the 45,324 Da of the native human IDO.

The heme content of rabbit small intestinal IDO was reported to be 0.8 mole of heme
per mole of enzyme [19]. Upon initial analysis of 6HisBDO, the heme content of the
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homogenous protein was low, approximately 0.4 mole per mole of enzyme, indicating
that 60% of the preparation was free from heme (i.e. an apoenzyme). A similar shortage
of heme was reported when a recombinant hemoprotein, nitric oxide synthase, was
overexpressed in a baculovirus expression system [128]. This lack of heme
incorporation was overcome by the addition of hemin during the induction phase. The
heme content of EDO was also increased by supplementation of the culture medium with

hemin during induction. This indicates that in E. coli EC538 cells, the rate of synthesis
of heme was not sufficient in the induction phase of the 6HisBDO protein. The heme
content of the recombinant protein was increased to 0.8 moles of heme per mole of
enzyme in the presence of excess heme, which is the same content as reported for the
rabbit intestional enzyme.

The expression conditions were therefore revised to include not only PMSF but also
hemin during the induction phase. The enzyme was purified with a 56% recovery from
the crude extract (approximately 30-fold) and yielded approximately 1.4 mg/L of
culture. The purified protein had a specific activity of 149 umoles kynurenine/h/mg
protein compared with 157 umol/h/mg enzyme for the placental enzyme [19], with Ltryptophan as the substrate.

An E. coli expression system, which incorporates a hexahistidyl tag, an efficient and
simple system for the expression and purification of recombinant human IDO, has been
developed. This system yields enzymatically active protein and overcame both the
difficulties associated with the purification of IDO from human placenta as well as the
low yield and activity observed for the recombinant GST fusion enzyme system.
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4. Characterisation of recombinant human

IDO
The size, purity and identity of the recombinant E D O protein were determined using
SDS-PAGE, Western blot and mass spectrometric analysis. As shown in chapter 3, the
protein expressed from EC538 (pREP4, pQE9-IDO) was found to have a molecular
weight of 46,976 Da by mass spectrometric analysis and was indistinguishable from
native human EDO by Western blot analysis. This analysis however, did not show
whether the addition of a hexahistidyl tag altered structural or enzymatic properties of
EDO.

Various techniques can be used to analyse recombinant proteins and allow for their
comparison to the native. These include spectroscopic techniques, specifically UVvisible spectroscopy, which for hemoproteins will display characteristic peaks in the
Soret region, for both ferric and ferrous states, and also give an indication of the heme
content of the protein. CD spectroscopy is also a useful technique as it provides
information about the secondary structure of the protein. The enzymatic activity of the
recombinant EDO can also be analysed with a range of substrates and compared to the
native. If the recombinant protein is found to closely resemble the native one, 6HisBDO
could be then used to infer structural features of native IDO.
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4.1 Comparisons of6HisIDO with native human IDO

4.1.1 Kinetic studies of6HisIDO

The substrate specificity and reaction rates for 6HisEDO were determined using
L-tryptophan, D-tryptophan and 5-hydroxy-L-tryptophan, all of which act as substrates
for native EDO [20]. EDO assays were undertaken using the standard assay system, as
described in Section 2.4.1, with varying concentrations of substrates. The turnover rate,

or reaction velocity (V), was plotted as a function of substrate concentration (S) (Figur
4.1 A, C and E). Using this data, Lineweaver-Burk double reciprocal plots were
constructed (Figure 4.1 B, D and F). These plots allowed determination of both the
Michaelis constant (Km), which is indicative of substrate affinity and the maximum
reaction velocity (VmaX). Due to the varying affinity of EDO for substrates, assays were
conducted using 0.19, 0.87 and 1.94 ug of protein for L-tryptophan, D-tryptophan and
5-hydroxy-L-tryptophan, respectively. Reaction velocities in the 96 well microplate
assay system were calculated assuming that an increase at A480 of 1 was equivalent to
77 nmoles of product produced per hour (determined using L-kynurenine as the
standard).

The x-intercept of double reciprocal plots is equal to -1/Km and the y-intercept is equal
to l/Vmax- The Km values were determined to be 20 uM, 5.0 mM and 400 uM for
L-tryptophan, D-tryptophan and 5-hydroxy-L-tryptophan, respectively. The Vmax values,
expressed as molecular activity (turnover rate), were 120 (L-tryptophan), 160
(D-tryptophan) and 5.3 (5-hydroxy-L-tryptophan) mol kynnurenine per min per mol
enzyme.
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Figure 4.1 Kinetic studies of 6HisIDO. (A) and (B) L-Tryptophan as substrate, conducted with 0.19 ug
6HisIDO per reaction; (C) and (D) D-tryptophan as substrate, conducted with 0.87 ug 6HisIDO per
reaction; (E) and (F) 5-hydroxy-L-tryptophan as substrate, conducted with 1.94 ug 6HisIDO per
reaction. (A, C , E ) Represent the graphs of substrate concentration versus turnover rate (V) in pinoles of
kynurenine produced per hour per m g of protein. (B, D, F) Lineweaver-Burk double reciprocal plots
where V refers to reaction velocity and S refers to substrate concentration. Linear trendlines were fitted
by least squares method using Microsoft Excel and equations are displayed on the graphs.

-79-

Chapter 4: Characterisation of recombinant human

IDO

4.1.2 Ultraviolet and visible spectroscopy

of6HislDO

The UV-visible spectrum of 6HisIDO in the ferric and ferrous form was examined and
compared with those of native IDO. The absorbance spectrum of oxidised (Fe24)
6HisIDO was recorded between 200 and 700 nm (Figure 4.2). The spectrum contained
peaks at 406 nm in the Soret region and 630 nm in the visible region. The Soret and

visible peaks were shifted to 420 and 560 nm by reduction with sodium dithionite. The
ratio of A40& to A280 in the oxidised form, which is indicative of heme content, was
determined to be 1.7.

Figure 4.2 Ultraviolet and visible absorption spectra of 6His-IDO The spectra of the purified IDO
sample (200 iag) dissolved in 0.5 m L of 50 m M Tris-HCl (pH 7.4) containing 1 m M E D T A were recorded
using a cuvette with a 10 m m pathlength. The reduced form of the enzyme was recorded after the
addition of ~2 m g of sodium dithionite to the ferric form. Bold line, the ferric form; thin line, the reduced
(ferrous) form. Inset: expanded region of the spectrum from 500-700 nm.
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4.1.3 Isoelectric Focusing of6HisIDO

The isoelectric point (pi) of a protein is the pH at which the net overall charge is equa
to zero. Because the overall charge is determined by the amino acid composition of
protein, pi values vary from protein to protein. By subjecting purified 6HisEDO to
isoelectric focusing, the pi of the protein was determined. 6HisEDO (200ng) was
applied to an isoelectric focusing column and electrophoresed in 1% ampholine (a
solution of amphoteric electrolytes) for 24 h. The pH gradient was then fractionated
into 3 mL fractions and the pH and EDO activity of each fraction was determined. As
shown in Figure 4.3, 6HisEDO eluted as a peak that corresponded to pH 7.1,
establishing that the pi of the enzyme was 7.1.
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Figure 4.3 Isoelectric focusing of 6HisIDO. Purified 6HisIDO (200 ug) was subjected to isoelectric
focusing using an L K B 8101 column in a 1 % (w/v) ampholine solution (pH 6-8) with a stepwise sucrose
gradient. Focusing was carried out at 500 V for 48 hr at 5°C. After electrophoresis, the p H grachent was
fractionated (3 mL/tube) and I D O activity in each fraction was determined.
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4.2 Further characterisations of6HisIDO

4.2.1 Preliminary NMR studies of6HisIDO

Nuclear magnetic resonance (NMR) spectroscopy is a technique that can provide
structural information on proteins. It is complementary to X-ray crystallography
because it is able to reveal structural information of proteins in solution. NMR is a
powerful technique for assigning residues surrounding the heme porphyrin ring, as these
undergo what is known as hyperfine shifts. Hyperfine shifts arise if a finite amount of

unpaired electron spin density is delocalised from the iron orbitals into the jt orbital
systems of the ligands i.e. the porphyrin nuclei, the proximal residue and the

coordinated distal residue. Since these interactions are through space, it would also be
expected to affect both the porphyrin ring and amino acid nuclei that are in close
proximity i.e. those that line the heme pocket above and below the heme.

To attain NMR data, the protein needs to be in a paramagnetic, low-spin state and this,
in theory for hemoproteins, is obtained by adding cyanide to the purified enzyme,
resulting in the ferric Fe3+CN" form. NMR analysis requires a relatively large amount
of protein, approximately 600 uL of 1-2 mM solution. Due to such a high
concentration, solubility and stability problems may be experienced during NMR
spectroscopy.

Initial NMR spectra were acquired with a low concentration (< 0.5 mM ) of 6HisEDO
using a 400 MHz NMR instrument. This 1-dimensional spectrum was promising, with

small hyperfine shifts observed, however in order to obtain detailed information a large
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concentration of protein was required and a larger magnetic field (600 MHz). A more
concentrated sample of 6HisIDO-CN was prepared and in conjunction with Dr John
Carver (University of Wollongong) and Dr Max Kenry (Australian National University)
spectra were acquired on a 600 MHz Varian instrument. The protein however
precipitated during the acquisition of data at room temperature. NMR spectroscopy was
attempted with ferric 6HisEDO-CN at 4°C however a poor signal was obtained. It was
concluded from these experiments, that in order to attain structural information using
NMR spectroscopy a 15N labelled protein may need to be expressed, which was outside
of the scope of this research.

4.2.2 Stability of6HisIDO

The stability of 6HisBDO was investigated to develop a buffer system that would allow
for long-term storage of the enzyme. Preliminary observations in our group had showed
that a Tris-HCl buffer resulted in greater stability than KPB, HEPES or MES buffer
systems for EDO. A more extensive stability study examined the effect of glycerol,
dithiothretiol (DTT), high salt (500 mM NaCl) and cyanide on the stability of 6HisBDO
(Figure 4.4.)

Samples of pure 6HisIDO in 50mM Tris-HCl (pH 7.4, EDTA ImM) had one of the
above components added and were then incubated for a period of 2 weeks at either
room temperature, or at 4°C. Stability was monitored by two means, observance of
visible precipitation and protein concentration of the solution. EDO activity was not
monitored, as the addition of some agents, such as DTT and CN" alter IDO enzymatic
activity and would need to be fully removed prior to the enzyme assay.
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Figure 4.4 Analysis of the stability of 6HisIDO. To purified 6HisIDO in Tris-HCl (50 m M , p H 7.4, 1
m M E D T A ) , glycerol ( 1 0 % (v/v), NaCl (500 m M ) , D T T (50 m M ) or N a C N (in excess) was added. (A)
Visual precipitation ranked from 0-10 where 0 indicates zero precipitation and 10 indicates m a x i m u m
precipitation observed. (B) Protein concentration of the supernatant, determined after the precipitate had
been pelleted by centrifugation. (C) Photographs of selected samples: (i) Day 0; (ii) Day 1 after
precipitate was pelleted by centrifugation; (iii) Day 14 and (iv) Day 14 after precipitate was pelleted by
centrifugation.
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Visual precipitation was monitored (Figure 4.4A), by the assignment of a rank between
0-10, where 0 indicates no visible precipitation and 10 indicates maximum precipitation.
After pelleting the precipitated protein by centrifugation, the protein concentration of
the supernatant was measured (Figure 4.4B). Figure 4.4C contains photographs at
selected time points during the stability trial. In all buffer groups 6HisEDO was more
stable at 4°C than at room temperature, with all of the treatments exhibiting some
precipitation when stored at room temperature.

The addition of DTT resulted in precipitation within one day and these results correlated
with a decrease in protein concentration. The CN" buffer showed low visual
precipitation, however the soluble protein concentration in the supernatant decreased.
The use of CN" in the buffer resulted in inactivation of EDO and therefore the CN"
would have to be removed prior to characterisation of the protein. Cyanide was
therefore not chosen for the storage buffer. Since the buffer containing glycerol
displayed a low level of visible precipitation and maintained a high protein
concentration in the supernatant; it was chosen for the long-term storage of 6HisEDO.

4.2.3 Circular dichroism spectroscopy of6HisIDO

Circular Dichroism (CD) is a powerful spectroscopic technique that allows the
elucidation of protein secondary and tertiary structure. CD analysis was undertaken on
purified 6HisBDO. Figure 4.5 shows the far UV CD spectrum obtained for an
approximately 1 uM solution of 6HisBDO. The 200-250 nm region is of importance
because it can provide information on the secondary structure of proteins. Absorbance
minima at 208 and 222 nm indicated the presence of a-helical structure and (3-sheet
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structure is indicated by a 217 nm trough. The spectral data can be further analysed

using deconvolution software (refer to section 2.4.8). Using this software the seconda
structure of 6HisIDO was determined to consist of 31% alpha helical, 11% beta sheet
and 58% random coil (with a square distance of 0.29 and a maximum error of 0.08,
acquisition number 5).
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Figure 4.5 Crcular dichroism spectrum of 6HisIDO. Circular dichroism spectrum of 6HisIDO (1
in 10 m M Tris-HCl (pH 7.4, 1 m M E D T A ) buffer. Spectrum was obtained in the far ultraviolet region.

4.2.4 Crystallisation o/6HisIDO

X-ray diffraction studies of crystallised proteins is the most a powerful technique f

elucidating protein structure. Crystallisation studies on 6HisIDO were conducted with
Dr Micheal Parker and Dr Galina Polekhina at the St Vincent's Institute of Medical
Research, (Victoria, Australia).
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Small crystals of 6HisIDO were obtained with protein that had been expressed and
purified in the presence of hemin, PMSF and EDTA. After purification, the protein was
exchanged into 50 mM Tris-HCl (pH 7.4, EDTA, 1 mM) containing 40% glycerol,
stored at -20°C and transported overnight on dry ice. Upon arrival in Melbourne, the
glycerol was removed by dialysis and small crystals were eventually obtained after
many trials (Figure 4.6). The crystals were grown in hanging drops at 4°C with
polyethylene glycol (PEG) 8000 used as a precipitant. The drops contained 2 uL of
protein (approximately 5 mg/mL) and 2 uL of the reservoir. To date, the crystals are

too small for X-ray experiments but the identification of a system that forms crystals i
promising.
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Figure 4.6 Crystals of 6HisIDO. Crystals of purified 6HisIDO. Crystals grew m hanging drops at 4°C
with polyethelene glycol 8000 as a precipitant.
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4.3 Discussion

Studies on EDO purified from rabbit intestine [40] and human placenta [20], have shown
that the ferrous (Fe2+) enzyme is active for the dioxygenation reaction. The ferrous
form however, is readily oxidised to the ferric (Fe3+) enzyme, which has no activity. A
reducing system, composed of ascorbic acid and methylene blue, is therefore required to
maintain the active ferrous enzyme during in vitro catalysis [37]. E D O activity
experiments reported here show that the recombinant enzyme also needs these two
cofactors for enzymatic activity in vitro.

Kinetic studies provide useful information on substrate affinity as well as reaction rates
T w o constants, K m and V m a x, were determined for 6HisBDO. K m is defined as the
substrate concentration at half the maximal turnover rate (1/2 Vmax) and is an indicator
of substrate affinity. V m a x is the m a x i m u m rate of reaction defined as amount of product
produced per unit time per unit of enzyme. Both constants can be determined from
Lineweaver-Burk double reciprocal plots. 6HisBDO was shown to oxidize D-tryptophan
and 5-hydroxy-L-tryptophan, in addition to L-tryptophan. The K m values were 20 u M ,
5.0 mM and 440 uM for L-tryptophan, D-tryptophan and 5-hydroxy-L-tryptophan,
respectively. These are similar to those of the native enzyme of 21 uM, 14 mM and 400
\JM, respectively [20]. The Vmax values, expressed as molecular activity (turnover rate),
were 120 (L-tryptophan), 160 (D-tryptophan) and 5.3 (5-hydroxy-L-tryptophan) mol
product/min/mol enzyme. These activities were also similar to those of the native
enzyme of 101, 294 and 6 mol product/min/mol enzyme [20]. These results indicate
that the addition of a hexahistidyl tag does not significantly affect the catalytic activity
of EDO. These results also show that L-tryptophan is the best substrate for h u m a n E D O
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and is likely, in vivo, to be the physiological substrate of the enzyme. Takikawa et al.
[20] came to a similar conclusion for human placental EDO.

The UV-visible spectrum was characteristic of a ferric (Fe3+) hemoprotein, and like that
of the native enzyme [20], exhibited characteristic peaks in the Soret and visible
spectrum. The 406 : 280 nm ratio of 1.7 is less than the ratio for the native enzyme, 2.2,
and this is consistent with the finding that the purified hexahistidyl tagged protein
contained approximately 20% apoprotein. The pi was determined to be 7.1 for
6HisEDO, which is close the predicted pi of 7. This result was in agreement with the pi
of 6.9 determined for the native enzyme [20], with the observed shift of approximately
0.2 expected from the addition of a hexahistidyl tag. These initial analyses of 6HisHDO
determined it to be essentially identical to the native human enzyme, in terms of
spectroscopic properties, cofactor dependency, substrate specificity and molecular
activity. Therefore 6HisEDO is a good model for studying the structure of the native
enzyme.

The overall goal of this research was to elucidate the structure of human EDO and
ultimately to design powerful EDO inhibitors. NMR spectroscopy, although a useful
technique for attaining structural information of proteins in solution, was not successful
in elucidating structural data on 6HisIDO. The poor signal observed in NMR studies

for 6HisEDO, may have been due to the relatively large size of the protein, difficulties in
obtaining and maintaining the paramagnetic low-spin state, or stability problems. This
technique could be further investigated, by incorporating a 15N label into the
recombinant protein.

-91-

Chapter 4: Characterisation of recombinant human

IDO

To date the most powerful technique in protein structure studies is the elucidation of the
crystal structure of the protein by X-ray crystallography. Once the recombinant enzyme
was shown to be comparable to the native enzyme, attempts were made to solve the
crystal structure of EDO. This included crystallisation of 6HisEDO with bound
inhibitors such as 6-chloro-D-tryptophan and 3-amino-2-napthoic acid. However, initial
crystallisation screens had limited success, with the protein precipitating instead of
forming crystals. The stability of the enzyme was then investigated in an effort to
develop a buffer system in which 6HisBDO was stable and that was also suitable for
crystallisation.

In order to identify a buffer that was optimal for the long-term storage of 6HisBDO,
glycerol, NaCl, cyanide or DTT was added separately to a Tris-HCl buffer. It was
thought that by adding CN, which binds strongly to the heme in EDO (reducing it to the
ferrous from) the stability of the EDO may be increased. DTT is also a reducing agent
that can be added to crystallisation buffer that may result in increased stability. The
addition of glycerol and high salt were also examined as these can increase stability and
may be used in crystallisation studies.

The addition of glycerol was found to be most effective in stabilising the enzyme. The
concentration was increased to 40% for long-term storage of the enzyme at -20°C as
under these conditions the sample would not freeze. This glycerol could be easily
removed by dialysis at 4°C. Small crystals of IDO were obtained using protein stored
in this manner. Although these crystals were too small for X-ray experiments, their
formation was promising. There are a number of potential reasons why larger crystals
did not develop. Crystallisation is difficult to achieve if the sample contains two very
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similar, but distinct protein forms. Like the native enzyme, purified 6HisEDO was
found to contain 20% of the apoenzyme and this may cause difficulties with
crystallisation. Also, the IDO samples may contain small concentration of degraded
protein. As discussed earlier (Section 3.3.4), the recombinant EDO initially underwent
degradation during purification, which was limited by the addition of PMSF. The
difficulties encountered with crystallisation may be attributable to low levels of
contaminant truncated IDO being present. Attempts to separate the full-length and
truncated protein were unsuccessful, therefore production of the truncated protein alone
(with retention of both structural integrity and enzymatic activity), may be a useful tool
in crystallisation studies.

Secondary structure can be studied using far UV CD analysis. A number of natural and
magnetic CD studies have been undertaken using EDO purified from rabbit intestine [37,
116, 117, 120, 121]. These studies however, focused on the heme environment looking
at 300-700 nm and did not analyse the 200-250 nm region. CD analysis of 6HisEDO
showed that the structure of human IDO contained a large amount of random coil with
approximately 30% alpha-helical and 10% beta-sheet. The large component of random

coil may contribute to the difficulties in gaining crystals. It should be noted that the CD
analysis was only preliminary, and would need to be more optimised to attain detailed
structural analysis.

Studies in this chapter indicated that the recombinant human EDO closely resembles the
native EDO; therefore it can be used as a source of IDO for detailed structural analysis.
After the development of a stable buffer system for storage and transport of 6HisEDO,
crystals were obtained.
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5. Site-directed mutagenesis of human

IDO
Site-directed mutagenesis is a technique that involves the in vitro manipulation of a
DNA sequence to give a specific product; these may include insertions, deletions and
substitutions to the sequence. In the case of human EDO, site-directed mutagenesis was
undertaken to identify amino acid residues important in heme/substrate binding. As
previously stated, the porphyrin ring of protoheme DC does not fill all the coordination
sites of the iron and residues from the protein coordinate to the heme through these
sites. It has been proposed that these coordinating residues are likely to be histidines.
Identification of these residues would provide insight into how heme binds and the
region of the heme binding site in IDO.

5.7 Production of mutants

Mutagenesis was undertaken using the GeneEditor™ in vitro site-directed mutagenesis
system (Promega, Australia), as outlined in section 2.3. In brief, this system used an
altered antibiotic resistance to select for clones carrying the desired mutation. A
mutation to the ampicillin resistance gene, creating a new additional resistance (to an
antibiotic selection mix), was conducted simultaneously with the desired mutation
reaction.
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5.1.1 Selection of mutagenesis targets

Site directed mutagenesis was undertaken to achieve two objectives; the first being the
identification of amino acid residues involved in either heme or substrate binding. The
second objective was the production of a C-terminally truncated protein, as observed as
a degradation product in the purification of 6HisEDO (See Section 3.3.4). To produce
this truncated protein, a mutagenesis reaction was undertaken to incorporate a stop
codon (TAG) at Lys 389.

Both CN" and CO, which bind heme with higher affinity than oxygen, competitively
inhibited IDO activity [14]. It was therefore proposed that heme was involved with
catalysis, and that the heme pocket is, or is close to, the substrate binding pocket in
EDO. The heme environment of rabbit intestinal EDO has been examined by EPR
studies, which have shown that the proximal heme ligand is a histidine residue [16].
Magnetic CD experiments have supported this and proposed that in the substrate-free
ferric form the distal ligand may also be a histidine residue [117-119]. In agreement

with this proposal, Suzuki et al. [28] suggested that the histidine residues at 303 and 34
were likely to be coordinated to the heme. This proposal was made because both of
these residues are highly conserved in the EDO and the IDO-like myoglobin species and
due to their proximity to each other i.e. they are only separated by 43 residues. These
residues were therefore selected as targets for mutagenesis. His16 was the only other
highly conserved His residue in the EDO and EDO-like myoglobin proteins and it was
therefore also selected as a target for mutagenesis.
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In order to identify other highly conserved residues, a sequence alignment of proteins
with homology to human EDO was constructed (See Figure 5.1). The human EDO
sequence [21] was aligned to that isolated from mouse [26] and rat [27]. The EDO-like
myoglobin protein sequences identified in Sulculus diversicolor aquatilis [28], Nordotis
madaka [29], Turbo cornutus [30] and Omphalius pfeifferi [31] were also aligned.
Although the sequence of TDO exhibits low identity to the EDO sequence, it has high
similarity (see Figure 1.3 and 5.1). Therefore, human [18], mouse (AC P48776) and rat
[32] TDO sequences were also aligned. This alignment confirms the finding of Suzuki
et al. [28] that there are only three highly conserved histidines. In addition to these
residues, a number of other conserved residues were selected as mutagenesis targets,
these being Val109, Asp274 and Lys352. The selection of these residues as targets for
mutagenesis is examined more closely in Section 5.5.1.
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HumanlDO
MouselDO
RatlDO
S.divMyo
NordMyo
OmpMyo
TurboMyo
HumanTDO
MouseTDO
RatTDO

1:....MAHAME
1:MALSKISPT*
1:MPHSQISPA*
1:
1:
1:
1:
1:
1:
1:

NSWTISKEYH
G*RR*LEDH*
G*RR*LE***
ADIQLSK**
ADIQLSK**
MPRLDVTQFE
MPRLDVAQFD
MSGCP
MSGCP
MSGCP

I.DEEVGFAL
*.**D*****
*.**D*****
V.SKDI**L*
V.SKDI**L*
V.SMKT**L*
V.SMKT**I*
FLGNNF*YTF
FAGNS**YT*
FSGNS**YT*

PNPQENLPDF
*H*LVE***A
*H*L*E***T
EPL*DV***Y
EPL*DV***Y
E**LTK**AY
E**LTK**AY
KKLPVEGSEE
K*LSMEDNEE
K*LSMEDNEE

YNDWMFIAKH:4 5
*SP*VLV*RN:49
*RP*ILV*RN:49
FAP*NRL**S:38
FEP*NRL**S:38
FDP*NNL*ST:39
FDA*NNLSSK: 39
DKSQTGVNRA:35
DRAQTGVNRA:35
DGAQTGVNRA:35

HumanlDO 46: LPDL IESGQLRERV EKLNMLSIDH LTDHKSQRLA
MouselDO 49:
** v * * * ^ * * * * * E * * * * P T * * T * G *RG*RL****
RatlDO
49:
**K* * * N * K * * * E * ***PT*RTEE *RG*RL****
S.divMyo 38:
**** VA*HKF*DA* KEMPL*DSSK *AGYRQK***
NordMyo
38:
**E* VA*HKF*DA* KEMPL*DQSK *AGYRQK***
OmpMyo
39:
MAQH VANKTM*DE* A**PV*DFNK *NGPNEVK*G
MSQ* VA*KGM*DE* K**PV*DFNK *NGPNEVK*G
TurboMyo 39:
HumanTDO 39:SKGGLIYGNY LHLEKVLNAQ *LQSETKGNK IH*EHLFIIT
MouseTDO 36:SKGGLIYGNY LQLEKILNAQ *LQSEVKGNK IH*EHLFIIT
RatTDO
36:SKGGLIYG*Y LQLEKILNAQ *LQSEIKGNK IH*EHLFIIT

RLVLGCITMA 89
H * A * * V * * * * 93
H*j\* * Y * * * * 93
H*Q*VL**SG 82
H*Q*VL**SG 82
H*Q*AMM*SG 83
H*Q*AMM*SG 83
HQAYELWFKQ 85
HQAYELWFKQ 85
HQAYELWFKQ 85

HumanlDO
MouselDO
RatlDO
S.divMyo
NordMyo
OmpMyo
TurboMyo
HumanTDO
MouseTDO
RatTDO

G***LTLGKG
G***L*FGKS
YMS*FEF*K*
YMA*FEF*K*
LENK
LENK
LENK

138
142
142
131
131
132
132
133
133
133
187
191
* *^* * * *ss*191
AQSVQN*LDG 173
GQA*QN*LDG 173
VPA*QN**DG 179
VPALQN**DG 179
*G*LQNMRVP 174
*G*LQSLRVP 174
*G*LQSLRVP 174

IHDHVNPKAF
MR*F*D*DT*
MR*F*D*DT*
MN*NLT*DH*
MNENLT*EH*
YGEKLPIEGL
FSEKLSADVL
VEAWLERTPG
VEAWLERTPG
VEAWLERTPG

FSVLRIYLSG: 236
* u * * * * * * * * . 240
* u * * * * * * * * . 240
YN***PF*G*: 222
YNGV*PF*N*: 222
*PKMWAFFG*: 228
*PKMWAFFG*: 228
LEP..HGFNF: 222
LEP..NGFNF: 222
LEP..HGFNF: 222

90
94
94
83
83
84
84
86
86
86

YVWGKGHGDV
***NR*DD**
***NR*DD*I
*L*QE*E*GA
*L*QE*E*GA
*L*QN*IDE*
*L*QN*LD**
IL*E..LDS*
IL*E..LDS*
IL*E..LDS*

RKVLPRNIAV PYCQLSKKLE
* * * * * * * * * i
***E**E**G
*******L* *
***E**E**G
VQR**ECV*K *LWNV*ND*G
VQR**ECVSK *LWNV*ND*G
PTS**NCL*A *LYGIYE*YD
PTS**NCL*A *LYGIYE*YD
*EIFQNGHVR DERNML*WS
*EIFQNGHVR DERNML*VIA
*EIFQNGHVR DERNML*VMT
HumanlDO 139 :PNKPLTYENM DVLFSFRDGD CSKGFFL.VS
MouselDO 143 . * * Q * M * * * * * * T * * * * pg* * * n * * * * * **
* p * * * * * **
143 • * * G * M * * * * * * j * * * * PG* *
RatlDO
E*MYNLPG*A
GT.EW**K*C
.DI
G.
.
.
S.divMyo 132
.DI E*MYNLPG*A GT.EW**K*C
NordMyo 132 G. . .
* * j GAIIDIPGDK KEWDW*VG**
APQ*
133
OmpMyo
**j
GPQ*
SAIVDIPADK KDWDWYIG**
TurboMyo 133
TMTA*DFNDF REYL*PAS*F Q*LQ*R*
HumanTDO 134 TMTA*DFNDF
Q*LQ*R*
MouseTDO 134 TMTA*DFNDF REYL*PAS*F Q*LQ*R*
REYL*PAS*F
134
RatTDO
HumanlDO 188: M Q M Q E . R D T L LKALLEIASC LEKALQVFHQ
M o u s e l D O 192 V E R * D . L K A * E***HD**TS ****KEI*KR
RatlDO
192: V E H * D . P K A * E***CS**AS ****KEI*KR
S.divMyo 174 AKAND.KAKM TSG*T*LTTT IGNMQAALAK
NordMyo 174: AKAND.KAKM A S G F T D L T A A IGNMQTALAR
OmpMyo
180: *DENN.D*KI A A * * K Q * * E A VANMQKMMGR
TurboMyo 180: *DENN.D*KI A A * * K Q * * E A AGNIQKTMGR
HumanTDO 17 5: YNRRHY**NF KGEEN*LLLK S*QEKTLLEL
MouseTDO 17 5: Y N R K H Y * * N F GGDYN*LLLK S*QEQTLLQL
RatTDO
175: YNRKHY**NF EGDYN*LLLK S*QEQTLLQL
HumanlDO 2 37: W K G . N P Q L S D
MouselDO 241: **C.SSK*PE
RatlDO 241: * * * * * K * p g
S.divMyo 223: FG*PASPI*G
NordMyo 223: FG*PASPI*G
OmpMyo
229: YGELT..*R*
TurboMyo 229: Y G E L T . . * H *
HumanTDO 223: *GKLEKNITR
MouseTDO 223: *GKFEKKILK
RatTDO
223: *GKFEKNILK

GLVYEGFWED
**L***V*DT
**L***V*DT
**I***VSDA
* *****VSDK
**IF**VKDQ
**IF**VKDQ
**EE*FIRIQ
**EE*FLKIQ
**EE*FLKIQ

.LPPILVYAD CVLANWKKKD
* * * * * c * * * **********
*****Q***
**********
.*K*V*T*G* VC*T*CRV*G
.*K*V*TF** IC*T*C*V*N
.I**VMT*G* II*N*SVA*G
.I**VMT*G* IL*N*AIA*G
RMHRVS*ILK LLVQQFSILE
RMHRW*IFK LLVQQFSVLE
RMHRW*IFK LLVQQFSVLE
LLVEIAAASA IKVIPTVFKA
* * * * * * * c j p * * *^* * * *SS*
*jy[*****3p*

PKEFAGGSAG QSSVFQCFDV LLGIQQTAGG: 285
* * M * S * * * * * * * * j * *5L* *****KHE**K: 289
* * K * S * * * * ****I**SL** ****KHDV*E: 289
*VTMI****A ***AM*LL*N ***VTHSPDK: 272
*VTMI****A ***TM*VL*G ****THSPEK: 272
*IKMK**N*S *TPTMRVL*N ****THPQDR: 276
*IKMK**N*S **PTLRVL*N ****ANQPER: 276
A**ESEEKEE *VAE**KQKE V*LSLFDEKR: 272
A*KDSEEKEE *MAE*RKQKE V*LCLFDEKR: 272
A*KDSEEKEE *MAE*RKQKE V*LCLFDEKR: 272
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HumanlDO
MouselDO
RatlDO
S.divMyo
NordMyo
OmpMyo
TurboMyo
HumanTDO
MouseTDO
RatTDO

286:GHAAQFLQDM
290:ESP*E***E*
290:*S**E***E*
273:Q...A**DEI
273:Q...A**DEI
277:N...A*IEEV
277:T...A*IEEI
273:EHLLSKGER
273:DYLLSKGER
27 3:DYLLSKGER

RRYMPPAHRN
* £ * * ******
*E******* *
SN**I***KQ
*N****S*KQ
LK*IQ*S**K
MK*IQ*N**K
*LSYRALQGA
*LSYRALQGA
*LSYRALQGA

HumanlDO
MouselDO
RatlDO
S.divMyo
NordMyo
OmpMyo
TurboMyo
HumanTDO
MouseTDO
RatTDO

335: CVKALVSLRS
339: **NG***V*K
339 **NG*****M
320 **A**TQY*T
320: * *A*F*OY* *
322: LKA*VSNF*N
322: LKA**SN**N
317: IDSLMTKW*Y
317: IDTLMTKW*Y
317 IDTLMTKW*Y

YHLQIVTKYI LIPASQQPKE NKTSEDPSKL EAKGTGGTDL: 384
p * * *\* D* T * * MK*SKKK*TD GDK**E**NV *SR* * * * *NP 388
"
p * * 2 * * DT* * VK*SK*K*MG GHK**E**NT * N R * * k k k k~\j •388
* * I *V** * * * VTASKSD
*P..KS* A Y * D * * K S * * : 361
* * I*V* ** * * VTASKSD
*P..KS* A Y * D * * K S * * : 361
S*V*V* * * * * VQAMEKN
LPAAKQG *L*PMKDSAM: 365
F*V*V* **** VQAFEKN
LPAAKQG *L*PMKESAM: 365
N*VCM* HRML GSK*
****SSG: 347
N*VCM* HRML GTK*
****SSG: 347
N*VCM* HRML GSK J
****SSG: 347

HumanlDO
MouselDO
RatlDO
S.divMyo
NordMyo
OmpMyo
TurboMyo
HumanTDO
MouseTDO
RatTDO

385:MNFLKTVRST
38 9:MTFLRSVKDT
38 9:MNFLRSVKDT
362:IPFLKEVRDD
3 62:IPFLKEVRDD
365: .KIVQGMRDD
365: .KTVQGFRDD
348:YHYLRSTVSD
348:YHYLRSTVSD
348:YYYLRSTVSD

TEKSLLKEG.
403
407
TEKALLSWP.
407
TKKALLSWP*
377
TEKMQK....
377
TEKVQQ....
376
CK
376
CK
RYKVFVDLFN LSTYLIPRHW IPKMNPTIHK FLYTAEYCDS 397
RYKVFVDLFN LSTYLVPRHW VPKMNPIIHK FLYTAEYSDS 397
RYKVFVDLFN LSSYLVPRHW IPKMNPIIHK FLYTAEYSDS 397

FLCSLESNPS .VREFVLSKG DAGLREAYDA
* * pp* * */\* p •kick-kit T * D U NED*TK**NE
* * C * * * * 7 \ * p .*****ILRR NED*K***NE
L*AD*TKM*R K*PQI*AEAK **N*SK**SG
M * A D * T N M * R K*PQV*AETK **N*TK*FNG
*IQAVAE..R Q L K G K * D A S * N***K**FG*
*IQAVGE..R N L K A R * D A S * N***K**FQG
LMIYFYREEP RFQVPF.... ..Q*LTSLMD
LMIYFYREEP RFQVPF.... ..Q*LTSLMD
LMIYFYREEP RFQVPF.... ..Q*LTSLMD

334
338
338
319
319
321
321
316
316
316

HumanlDO
MouselDO
RatlDO
S.divMyo
NordMyo
OmpMyo
TurboMyo
HumanTDO 398:SYFSSDESD:406
MouseTDO 398:SYFSSDESD:406
RatTDO
398:SYFSSDESD:406

Figure 5.1 Sequence alignment of IDO, IDO-like myoglobin and T D O proteins. Alignment of human
[21], mouse [26] and rat [27] IDO, and the IDO-like myoglobin proteins (Myo) isolatedfromSulculus
diversicolor aquatilis (S. div) [28], Nordotis madaka (Nord) [29], Turbo comutus (Turbo) [30] and
Omphalius pfeifferi (Omp) [31] as well as human [18], mouse (AC P48776) and rat [32] T D O . The
histidine residues are highlighted in red and the other mutated residues in green.
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5.1.2 Design of mutagenic primers

Once the mutation targets had been selected, mutagenic oligonucleotides we

The primers were 21 to 45 bases in length, with the desired base change in
the centre. The oligonucleotide sequences are outlined in Table 5.1.

Table 5.1 Mutagenic primer sequences. Sequence of primers used for the site-directed mutagenesis of
6HisIDO. The blue sequence indicates the codon present in IDO and the red sequence indicates bases in
the desired mutation.

Mutation Primer
To Ala

His16

His
3' ATGCATTAA....5'
5'-ATC A G T A A A C A G T A C G C T A T T G A T G A A G A A GTG-3'
Ala
His

His

303

3' CGACACTCC...5'
5'-AGA AGA TAT ATG CCA CCA GCT GCT AGG AAC TTC
Ala
CTGTGCTCATTA-3'
His

His346

Val104

Asp 274

J
Lys,352

To STOP

LysS389

3' ATGCATGAC 5'
5'-TCC CTG AGG AGC TAC GCT CTG CAA ATC GTG ACT-3'
Ala
Val
3'CGAGTTGGA...5'
5'-AAT ATT GCT GCT CCT TAC TGC-3'
Ala
Asp
3' AAAGACCAG...5'
5'-GTC TTT CAG TGC TTT GCT GTC CTG CTG GGC ATC-3'
Ala
Lys
3' TGAAAG ATG...5'
5'-CTG CAA ATG GTG ACT GCG TAC ATC CTG ATT CCT-3',
Ala
Lys
3' GACAAGTGA...5'
5'-TTA ATG AAT TTC CTG TAG ACT GTA AGA AGT ACA-3'.
STOP
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5.1.3 Site-directed mutagenesis reactions

The site-directed mutagenesis protocol followed is described in section 2.5. Initially
plasmid DNA (pQE9-IDO) was isolated from EC538 (pREP4, pQE9-IDO) cells and
alkaline denatured. In addition to the desired mutation, the antibiotic selection mutation
was simultaneously made to the DNA; this is referred to as the selection mutation. The
selection mutation altered the ampicillin resistance gene of the plasmid, so only those
colonies that carried the selection mutation would grow in the presence of a
commercially available selection antibiotic mix, in addition to ampicillin. After the
DNA had been alkaline denatured, both the desired mutagenic oligonucleotide and the
selection oligonucleotide were annealed to the dsDNA template. The addition of T4
DNA polymerase and ligase synthesised the mutant strand and the DNA could then be
transformed. An initial transformation into E. coli BMH mutS cells was undertaken to
suppress in vivo mismatch repair. After a 14-16 h growth period, the DNA was isolated
from the BMH mutS cells and transformed into E. coli JM109 cells. This
transformation was used to ensure proper segregation of mutant and wild type plasmid.
The transformed JM109 cells were grown in the presence of the ampicillin selection
mix and were therefore selected as carrying at least one of the mutations, i.e. the
selection mutation. These colonies were then screened further to identify clones that
also carried the desired mutation.
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5.1.4 Identification of clones carrying the desired mutation

Initially, colonies were screened by enzymatic digestion with the restriction enzyme
Sail. Clones that released a 1.2 kb fragment, corresponding to the EDO gene, were
further analysed by DNA sequencing. His16 was sequenced using the Typell primer,
Val109 with the IDO/Up, Asp274 with IDO/Down and His303, His

346

, Lys352 and sLys389

with the pQE9/Reverse sequencing primer (refer to Table 2.1 for sequencing primer
details). Electropherograms of the clones that carried the desired mutations are shown
in Figure 5.2. Once identified, the mutated pQE9-IDO DNA was transformed into
E. coli EC538 (pREP4) cells for expression and purification.
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B

His16 to Ala16

5' GAGTACGCTATTGAT 3'

iu

ULM

3' GAGTACCATATTGAT 5'
Asp 274 to Ala274

5' TGCTTTGCTGTCCTG 3'

IDO

109 t A1Q109
Val109
to Ala
n

5' ATTGCTGCTCCTTAC 3'

\IMOA

5' ATTGCTGTTCCTTAC 3'
D Lys352 to Ala352
3' GTACATGCGTCAGTG 5'

5' GATGTACGCAGTCAC3'

J.kkJJ^i/iJAlJ cdJ&£L
5' TGCTTTGACGTCCTG 3'
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His 346 to Ala 346

IDO

-T

H i s 3 o 3 1 0 A i a 303

3' AACGTCTCGCATCGA 5' 3' CAAGGATCGTCGACC 5'
5' TTGCAGAGCGTAGCT 3' 5' GTTCCTAGCAGCTGG 3'

3' AACGTCTACCATCGA 5'

3' CAAGGACACTCGACC 5'

G Lys389to STOP
3' ATGTCAGATGTCCTT 5'
5' TACAGTCTACAGGAA 3'

\

3' ATGTCAGAAGTCCTT 5'
Figure 5.2 D N A sequence analysis of mutant pQE9-IDO. Electropherograms of D N A carrying the
desired mutations to human recombinant IDO. The sequence above the peaks refers to the mutant
sequence and the one below is the sequence as it appears in human I D O (A) His15 to Ala mutant;
(B) Val109 to Ala mutant; (C) Asp 274 to Ala mutant, (D) Lys 352 to Ala mutant; (E) His346 to Ala mutant;
(F) His303 to Ala mutant and (G) Lys 389 to stop mutant.
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5.2 Expression of IDO mutants

E. coli strains in which a single residue was substituted for alanine were designat
EC538 (pREP4, pQE9-His16IDO), EC538 (pREP4, pQE9-His303IDO), EC538 (pREP4,
pQE9-His346IDO), EC538 (pREP4, pQE9-Val109IDO), EC538 (pREP4, pQE9Asp274IDO) and EC538 (pREP4, pQE9-Lys352IDO). All of these were expected to

express a protein in which a hexahistidyl tag was attached to a full size IDO, with
single residue change. This expression plasmid EC538 (pREP4, pQE9-sLys389) was

expected to express a protein in which a hexahistidyl tag was attached to a truncat
IDO, in which 15 amino acids were removed from the C-terminus. The predicted
molecular weights of the hexahistidyl tagged mutant proteins are outlined in Table

Table 5.2 Predicted molecular weights of mutant 6HisIDO. The predicted molecular weight of the
expressed mutated 6HisIDO proteins.

Predicted molecular weight
Mutant
(Da)
_ _ .

"His^His^andHis^
46948

Val 109

46932

Asp274

46919

Lys352

45530

sLys

389

To ensure that these strains were expressing the mutant IDO protein, each was induc
with IPTG (10 uM), in the presence of hemin (7 uM), for 3 h in a 100 mL culture.
Crude lysates were examined by SDS-PAGE (Figure 5.3A). The presence of an

additional band of approximately 45 kDa was observed in all lanes. This was confirm
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to be I D O by Western blot analysis using a polyclonal antibody raised against purified
6His-IDO (Figure 5.3B).

34.9 —
29.9—

21.8—

Figure 5.3 S D S - P A G E and Western blot analysis of mutant I D O protein expression. Crude cell
lysate of EC538 (pREP4) containing; Lane (1) pQE9; Lane (2) pQE9-IDO; Lane (3) pQE9-His 346 IDO;
Lane (4) pQE9-His 303 IDO; Lane (5) pQE9-Asp 274 IDO, Lane (6) pQE9-Val 109 IDO; Lane (7) pQE9Lys 352 IDO; Lane (8) pQE9-His 16 IDO and Lane (9) pQE9-sLys389IDO. Strains were induced using IPTG
(10 (J;M) with the addition of hemin (7 \M) for 3 h. (A) Coomassie brillant blue stained 1 2 % acrylamide
S D S - P A G E gel. (B) Western blot analysis detected using a rabbit polyclonal antibody raised against the
6HisIDO. The sizes of molecular mass markers (in kilodaltons) are indicated and presence of I D O is
indicated by arrows.
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5.3 Purification of IDO mutants

Once it has been established that all of the mutant strains expressed a recombinant
human IDO protein, as confirmed by Western blot analysis, each mutant protein was
purified for further characterisation. Based on the yield of 6HisIDO of 1.4 mg of pure
protein per litre of culture, a 4 L culture of each mutant was expressed. This was
expected to result in approximately 5 mg of each mutant being purified. This would

provide sufficient material to undertake preliminary characterisation of the IDO mutants
including UV and visible spectroscopy, CD spectroscopy and analysis of the kinetic
properties of each mutant.

Protein expression and purification of each mutant was conducted as per the protocol
developed for the recombinant 6HisIDO, with minor modifications. The cultures were
induced at an absorbance at 600 nm of 0.6-0.8 with IPTG (10 pM), in the presence of
hemin (7 uM) and PMSF (1 mM), for 3 h. EDTA was then added at a final
concentration of 1 mM at the end of culturing and the cells were harvested by
centrifugation. So that all proteins could be analysed concurrently, each mutant was
expressed and the cells stored for up to two months (-80°C). All of the mutants were
then purified within a three week period.

The cells were lysed using sonication as outlined in Section 2.3.1. This step was
repeated twice to obtain the maximum protein yield. After lysis of the cells,
approximately 40 mL of crude lysate was loaded onto a phosphocellose column (o 2 x
1.5 cm) and after extensive washing with 50 mM KPB, samples were eluted on a linear
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potassium phosphate buffer gradient (100-500 mM, 50 mL each). The cation exchange
chromatography elution profiles for the mutants were similar to those obtained for
6HisIDO and were monitored at 280 and 406 nm. For some mutants, however, there
was no 406 nm absorbance, indicating an absence of heme. This was also indicated by
a lack of red colouration of the protein, this red colouration being characteristic of
hemoproteins. The combined protein peak was then loaded onto the Ni-NTA column
(o 2 x 1 cm) and after washing with 10 mM imidazole buffer, the protein was eluted
with a linear imidazole gradient (50-250 mM, 50 mL each). The elution profiles were
monitored at 280 and 406 nm, for those mutants that absorbed in the soret region. A
dialysis step was then used to exchange the buffer to Tris-HCl (50 mM, pH 7.4, 1 mM
EDTA) and the protein was then concentrated to a volume of 1-3 mL. The yield of
purified protein ranged from 0.2 to 1.2 mg of protein per litre of culture. After
purification, the proteins were stored in Tris-HCl (pH 7.4, 1 mM EDTA, 40% glycerol)
at -20°C, until all mutants were purified. All mutants were then analysed
simultaneously.

After purification the mutants were analysed by SDS-PAGE and Western blot analysis
(Figure 5.4). As can be seen by SDS-PAGE, only one homologous band was observed
for each protein with a molecular weight of approximately 45 kDa. These bands were
again confirmed to be human IDO by Western blot analysis against a polyclonal
antibody raised to purified 6HisIDO.
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A
1

2

3

4

5

6

7

8

97.4 —
66—
45 —

31—*

21.5™

B
1 _J_ 3 4 5 6 7 8
116 —
80 —

52.5 —I
34.9 —

29.9 —I
21.8 —

Figure 5.4 SDS-PAGE and Western blot analysis of purified IDO mutants. Purified protein from
EC538 (pREP4) containing; Lane 1, pQE9; Lane 2 pQE9-IDO; Lane 3, pQE9-His 346 IDO; Lane 4, pQE9His303IDO; Lane 5, pQE9-Asp 274 IDO, Lane 6, pQE9-Val 109 IDO; Lane 7, pQE9-Lys 352 IDO; Lane 8,
pQE9-His 16 IDO; Lane 9, pQE9-sLys389IDO. (A) Coomassie brillant blue stained 1 2 % acrylamide SDSP A G E gel of approximately 2 |xg of protein. (B) Western blot analysis using a rabbit polyclonal antibody
raised to the 6HisIDO. The sizes of molecular mass markers (kDa) are indicated.
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5.4 Characterisation of IDO mutants

The molecular weight of each of the mutants was determined to be approximately
45 kDa by SDS-PAGE analysis. They were then confirmed to by IDO by Western blot
analysis. To determine whether the mutations had resulted in an altered secondary

structure, heme binding properties and/or the kinetic properties each of the mutant

were further analysed by UV and visible and CD spectroscopy. The kinetic properties
of each of the mutants with a range of substrates were also analysed.

5.4.1 Ultraviolet and visible spectroscopy of IDO

mutants

UV and visible spectroscopy was conducted on all purified mutants (Figure 5.5). The

ratio of the absorbance maxima at 406 to 208 nm is outlined in Table 5.2. From this
data it may be deduced that the heme content of each mutant was highly variable.
His346 and Asp274 have very low or no absorbance at 406 nm, indicating that they did

not bind heme. This confirms the observations made during the purification that thes
proteins had no visible red colouration.

Table 5.3 Absorbance ratios of purified I D O mutants. The ratio of absorbance maxima at 280 and
406 n m for the purified IDO mutant proteins.

Mutant
His346
His303
Asp274
Vall09
Lys352
Hisl6
sLys389

406 : 280 n m
0
0.91
0.10
1.62
0.78
1.00
0.81
-109-
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Figure 5.5 Ultraviolet and visible spectra of I D O mutants. The UV-visible spectra of the purified IDO
mutants (approximately 1 mg/mL) dissolved in 50 m M Tris-HCl (pH 7.4 containing 1 m M E D T A ) .
Spectra were recorded from 250-550 nm.

5.4.2 Kinetic studies of IDO mutants

The K m and V m a x values were determined for each of the I D O mutants. A s with
6HisIDO, each mutant was analysed using L-tryptophan, D-tryptophan and
5-hydroxy-L-tryptophan as the substrate. Due to the different affinity of each of these
substrates to IDO, the amount of protein used in each assay system was determined by
trial and error so that the initial rate of reaction could be determined. Each mutant
sample was a mixture of active holoenzyme (heme containing IDO) and inactive
apoenzyme (heme-free IDO), the reaction velocity was determined as a function of
concentration of holoenzyme. The concentration of holoenzyme for each mutant was
determined using the extinction coefficient determined for rabbit intestinal IDO of
e = 140 mM'cm"1 [16]. The amount of holoenzyme (pg) used in each assay is outlined
in Table 5.4
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Table 5.4 Protein concentrations for mutant I D O kinetics. The amount of heme protein used in each
assay to determine V m a x and K m .

L-Tryptophan
(fjg heme)

D-Tryptophan

5-Hydroxy-L-tryptophan

(/jg heme)

(/jg heme)

His1*

61)7

67l4

6769

Val 109
His 303
Lys 3 5 2

0.09
0.08
0.08

0.19
0.16
0.12

0.93
0.78
0.80

s389

A s with 6HisIDO, substrate concentration (S), verses velocity (V) plots were
constructed for each mutant, with L-tryptophan, D-tryptophan and 5-hydroxy-Ltryptophan as substrates (Figure 5.6 A , C, E, G and I). Double reciprocal plots were
also constructed and linear trendlines were fitted by least squared method from which
the constants K m and V ^ were determined (Figure 5.6 B , D, F, H and J). The K m and
V m ax values are summarised in Table 5.5 and 5.6, respectively.

Table 5.5 Kn, values for I D O mutants. The K m values determined for the I D O mutants with Ltryptophan, D-tryptophan and 5-hydroxy-L-tryptophan. N D indicates values that were not determined as
the mutant enzymes failed to display detectable enzyme activity

L-Tryptophan D-Tryptophan

5-Hydroxy-L-tryptophan

(fM)

(mM)

(iM)

w

5.58

2.44

"140

Val 109

8.87

5.32

100

His 303

9.42

1.92

100

His 346

ND

ND

ND

Lys 3 5 2

20.05

4.36

170

Asp 2 7 4

ND

ND

ND

sLys 389

7.64

4.65

210
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F Ig ure5.6 Kinetics studies of I D O mutants. (A, B ) His 16 I D O mutant; (C, D ) Val 109 I D O mutant; (E,
F)His I D O mutant; (G, H ) Lys 352 I D O mutant and (I, J) sLys389 I D O mutant, (i) L-Tryptophan as
substrate; (n) D-Tryptophan as substrate and (iii) 5-hydroxy-L-tryptophan as substrate. (A, C , E , G, and
I) represent the graphs of substrate concentration versus turnover rate (V) in umoles of kynurenine
produced per h per m g of heme. (B, D, F, H and J) Lineweaver-Burk double reciprocal plots where V
refers to reaction velocity and S refers to substrate concentration. Linear trendlines were fitted using
excel and equations are displayed on graphs. The amounts of protein used for each assay are shown in
Table 5.4.
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Table 5.6 V m a i values for I D O mutants. The V m a x values determined for the I D O mutants with Ltryptophan, D-tryptophan and 5-hydroxy-L-tryptophan. N D indicates values that were not determined as
the mutant enzymes failed to display detectable enzyme activity.

L-Tryptophan

D-Tryptophan

5-Hydroxy-L-tryptophan

(mol product/min/mol (mol product/min/mol (mol product/min/mol
holoenzyme) holoenzyme) holoenzyme)
_ _

ffls16^

15.36

39.69

Val 109

5.81

29.87

0.73

His 303

25.72

44.68

1.4

His 346

ND

ND

ND

Lys 3 5 2

25.39

34.00

2.93

Asp 2 7 4

ND

ND

ND

S Lys

389

116.74

63.77

1.59

A s can be seen from the above tables, the K m for each of the mutants was between
5-20 for L-tryptophan (uM), 1.9-5.3 for D-tryptophan (mM) and 100-210 for
5-hydroxy-L-tryptophan (uM), respectively. The Vmax values for each of the mutants
ranged between approximately 6-64 for L-tryptophan, 34-117 for D-tryptophan and
0.7-3 mol product/h/mol holoenzyme for 5-hydroxy-L-tryptophan.

5.4.3 Circular dichroism spectroscopy of IDO

mutants

CD spectra were acquired to determine what effect each mutation had on the secondary

structure of the proteins. This was particularly important for the mutants of His346 and
Asp274, which did not bind heme and thus had no enzymatic activity. If secondary

structure was maintained in these mutants, then loss of heme binding could be attribut
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to the effect of the mutation on enzyme activity and not because the mutation had

resulted in a loss of secondary structure. As with 6HisIDO, the far UV CD spect
obtained (Figure 5.5) and this data was analysed using the K2D deconvolution
program. These results are summarised in Table 5.7.
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Figure 5.7 Circular dichroism analyses of 6HisIDO mutants. Circular dichroism spectra of IDO
mutants in 10 m M Tris-HCl (pH 7.4, 1 m M E D T A ) buffer. The far U V region from 200-250 n m is
shown.

Table 5.7 Secondary structure analyses of 6HisIDO mutants. The secondary structure composition of
each of the IDO mutants.

Mutant

Alpha
Helical
(%)

Beta
Sheet
(%)

Random
Coil
(%)

His346
His303
His 16
Val109
Asp 274
Lys352
sLvs389

28
31
30
29
31
31
30

18
10
16
16
10
11
16

53
59
53
55
59
59
54
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5.5 Discussion

Site-directed mutagenesis is defined as the in vitro manipulation of a DNA sequence to
yield a specific product. It is a powerful molecular biology technique and can be used

to create specific insertions, deletions or substitutions in particular sequences. There ar
many commercially available kits for site-directed mutagenesis and most incorporate
some form of selection. The selection may be the addition of a restriction site, however,
a difficulty of working with altered restriction sites is the need to identify a unique
restriction site and this may be difficult when working with a large insert. Another form

of selection, as with the kit used, is the alteration of an antibiotic resistance gene. The
use of an altered antibiotic restriction gene for mutagenesis selection was preferred
because it allowed for in vivo targeting of mutants by growth in the presence of an
antibiotic mix.

5.5.1 Selection of targets for IDO mutations

Selection of targets for mutation was hindered by the lack of structural information on
IDO. The establishment of large protein sequence databases and powerful structural
prediction software is widely used when structural information is lacking. This
software searches databases for proteins whose structures are known and that contain
homology to the protein of interest. This information may be used to predict the
structure of the protein of interest. Although myoglobin and hemoglobin are two of the
most extensively studied heme proteins, both have low sequence homology to IDO.
The only proteins that had sufficient sequence homology to EDO were the IDO-like
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myoglobins. Like EDO, their 3-dimensional structures have not been solved to date.
Thus the EDO structure could not be predicted in this manner. Mutant residue selection
was therefore based mainly on the primary amino acid alignment (Figure 5.1).

It was proposed by Shimizu et al. [16] in 1978 that the proximal ligand of the heme in
EDO was an imidazole nitrogen. This was later confirmed by Uchida et al. [119] and
Sono and Dawson [117] who also reported that in the substrate-free state, ferric EDO

had a histidine as the distal ligand. As previously stated, of the twelve histidine residu
in human EDO, only three of these His16, His303 and His346 are highly conserved and
because of their proximity, it was proposed by Suzuki et al [28] that His and His
may be the residues coordinated to the heme. In order to investigate this, these
histidines were mutated to alanine.

In addition to the histidine mutations, a number of residues in highly conserved regions
were selected. Asp274 is located in a highly conserved region between residues 260-290
(see Figure 5.1) and is itself conserved in all EDO and EDO-like myoglobin species.
Aspartic acid can potentially coordinate to the heme group through its carboxylate
group. This residue was therefore selected as a target for mutagenesis. Lys352, while
not conserved in mouse and rat IDO, is conserved in all the EDO-like myoglobin species
and is located in a run of homologous residues following His and as such, may be
located in the heme binding pocket. The nitrogen group of Lys352 may be involved in
heme binding. This residue was therefore selected as a target for mutagenesis. Val109,
which is not located in a conserved region, was randomly selected as a control for

mutation. It is unlikely that Val109, a relatively small and aliphatic amino acid, is in the
active site or involved in heme coordination.
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Thefinalmutation undertaken w a s the incorporation of a stop codon at Lys 3 8 9 (sLys389).
A s previously discussed, difficulties had been encountered in the crystallisation of
purified 6HisIDO. These m a y be attributable to small amounts of truncated protein
being present, such that the protein sample was actually a mixture, hindering the
crystallisation process. The ability to produce the truncated protein alone, if it retained
activity, m a y aid the crystallisation process. The sLys 389 protein produced would have
15 amino acids lacking from the C-terminus. This is one more residue than in the
truncated protein observed during purification of the 6HisIDO, however, attempts to
produce a 14 amino acid truncated protein {i.e. the incorporation of a stop codon at
Thr

) were unsuccessful, with no clones carrying the desired mutated identified, after

multiple reaction cycles, with a mutagenic primer of 45 bases in length.

5.5.2 Production of IDO mutants

After the mutation targets were selected, primers were designed that were initially 21
residues long, which corresponded to 9 bases on either side of the codon to be altered.
Although the Promega Corporation recommended this primer length, after a number of
repetitions of the mutagenesis reaction and screening of more than 30 colonies for each
mutation, only one mutant, Val 109 , was identified. Longer primers (33 bases) were
therefore synthesised. This resulted in His 16 , His 346 , Asp 274 , Lys 3 5 2 and sLys 389 being
produced. For His 303 however, an even longer mutagenic primer of 45 base pairs, which
is 21 bases on either side of the codon, was required to successfully mutate the residue.

In addition to increasing the primer length, other difficulties were encountered with the
mutagenesis protocol. O n e of these was poor growth of both the E. coli B M H - w w / S and
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J M 1 0 9 transformed cells in the presence of the antibiotic mix. This was overcome by
halving the recommended amount of antibiotic selection mix used. This may have been
due to pQE9-IDO having reduced (^-lactamase expression and thus requiring reduced
levels of selection antibiotic. The other difficulty encountered in this study was
obtaining DNA sequence analysis whilst screening for the clones carrying the desired
mutation. After continual attempts to gain DNA sequence information, it was decided
to incorporate an initial screening of the DNA for the IDO insert by enzymatic digestion
with Sail. Some colonies appeared to have lost the EDO insert during the mutation
process. If digestion with Sail released a 1.2 kb fragment, then there were no further
difficulties encountered in gaining sequence information. It is worth noting, that if a
colony carrying a desired mutation was not located after screening approximately six
colonies, then routinely, no colonies carrying the desired mutation were found and the
mutagenic reaction had to be repeated.

After DNA carrying the desired mutation was identified, it was transformed into EC538
(pRE4) as this was determined to be the most suitable strain for 6HisIDO expression
(Section 3.2.1). Small scale induction and Western blot analyses confirmed that human
IDO protein was being expressed. Larger scale cultures were undertaken so that enough
protein could be purified for preliminary characterisation.

The expression and purification system used for the mutants was the same as that
optimised for 6HisIDO, with a modification that the E. coli pellets underwent two
sonication steps. Based on the yield from 6HisIDO purification it was predicted that
from a 4 L culture approximately 5 mg of protein would be purified. The yield for
some mutants, however, was lower than 1 mg. The main cause of these lower than

-128-

Chapter 5: Site-directed mutagenesis of human

IDO

expected yields can be attributed to the different physical properties of the proteins, in
particular the heme content. The cation exchange chromatography elution profiles for
the mutant proteins were similar to those obtained for 6HisIDO, however, difficulties
were encountered during the affinity chromatography step. Some proteins had a low
406 nm absorbance and the use of 280 nm to track elution was hindered because the
protein was eluted using an imidazole gradient and imidazole also absorbs at 280 nm.
This may have attributed to the low protein yields for some mutants. The optimisation
of the expression and purification of each mutant would result in better purification
yields.

5.5.3 Analysis of alanine substituted IDO mutants

Analysis of the mutants was primarily conducted to determine whether they were still
enzymatically active. If enzymatic activity were lost, this analysis would indicate
whether this was due solely to the residue alteration or as the result of an overall loss
secondary structure.

SDS-PAGE analysis of the purified proteins showed that from each preparation a single
homologous band was obtained with a molecular size consistent with that observed for
human IDO. These were all confirmed to be EDO by Western blot analysis using a
polyclonal antibody raised to 6HisEDO. As with 6HisEDO the mutant proteins were
expected to be relatively unstable. Therefore all purified protein was stored in Tris-HCl
(50 mM, pH 7.4, 1 mM EDTA) 40% glycerol at -20°C for as short a time as possible.
All proteins were purified concurrently and characterised simultaneously, so the longest
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a protein sample was stored was 6 weeks. Although it was determined that I D O was
most stable in the Tris-glycerol buffer system, activity may still be lost upon storage.

The UV-visible spectra of the purified mutants showed that the heme content of each of
the mutants was highly variable. The 406:280 ratios were lower than the value of 1.7
observed for 6HisEDO, indicating that a larger amount of the apoprotein was being
expressed. Due to the low amounts of protein purified, the heme concentration could
not be determined accurately using the alkaline pyridine hemochrome method. These
mutants were expressed with the addition of 7 uM hemin during induction, as was done
for 6HisIDO, however the varying heme concentrations indicated that for each mutant
strain expression conditions may need to be optimised. For Asp274 and His346, the 406
nm absorbance indicated that the heme content was extremely low. This suggested that
the mutations had affected the ability of heme to bind in IDO. To ensure that the
secondary structural integrity of the mutations was maintained, CD analysis was
undertaken.

The CD spectra showed that all mutants contained approximately 30% alpha helical,
15% beta sheet and 55% random coil structure. This is consistent with that observed for
6HisEDO (refer to section 4.2.3). In order to acquire CD spectra, the glycerol was
removed from the storage buffer and the buffer concentration was diluted to 10 mM so
that they did not absorb in the far UV. The samples were run at room temperature. The
proteins were unstable under these conditions and, if left for extended periods,
precipitated. From this CD analysis it could be concluded that all of the mutants

maintained secondary structure and that any loss of activity could therefore be attribute
to the affect of the residue change and not the overall loss of secondary structure.
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Each of the mutants was analysed for their ability to oxygenate L-tryptophan,
D-tryptophan and 5-hydroxy-L-tryptophan. Each mutant, excluding Asp274 and His346,
was able to convert each of these substrates to N'-formyl kynurenine. The Km and Vmax
values obtained were compared to those obtained for 6HisIDO (see section 4.1.1) and
placental human IDO, as reported in Takikawa et al. [66]. The Km values indicate the
affinity of the enzyme for each of the substrates. For L-tryptophan the mutant Km
values were between 6 and 20 uM. These are comparable to those of 6HisIDO (20 pM)
and placental human EDO (21 uM). For D-tryptophan the Km values ranged between 2
and 5 mM and these are comparable to the 5 mM determined for 6HisEDO, but are low
in comparison to the reported Km of 14 mM for placental IDO. Because mutagenesis
was carried out on the recombinant protein, values of around 5 mM were as expected.
The reported Km values for 6HisEDO of 440 uM and native EDO of 400 uM were
approximately double that obtained for the mutants. Km is indicative of the affinity of
the substrate for the enzyme; the mutants had the highest affinity for L-tryptophan,
followed by D-tryptophan and 5-hydroxy-L-tryptophan. This agrees with both the
6HisIDO result and the previously reported data for the human placental enzyme [66].

The rate of reaction for the IDO mutants had to be determined differently to that
previously described because of the varying heme content of each enzyme. Only
enzyme that contained heme would have been able to catalyse the oxidative cleavage

reaction. Therefore the rates of reactions were calculated as a function of heme content
This was determined using the extinction coefficient for rat IDO at 406 nm as
previously reported [16]. The Vmax values were determined for each of the mutants, and
even though they were calculated as a function of heme content, the values obtained
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were still low w h e n compared to those obtained for 6HisIDO and native EDO. Each of
the V m a x values however, were highest for D-tryptophan, followed by L-tryptophan, with
5-hydroxy-L-tryptophan having the lowest V m a x values. The low V
m a y be due to the relative instability of the enzymes.

m x

values obtained

The primary aim of the

characterisation of the mutants was to establish whether the mutations were pure and if
they maintained secondary structure and enzymatic activity. The extensive optimisation
of the expression and purification of each mutant was outside the scope of this research.
It should however be noted that the stability of each of these mutant proteins was not
extensively examined, and the low V m a x values might be attributed to the instability of
the enzyme during purification and storage. It was decided to analyse the mutants
simultaneously, which meant that the mutants had been stored in Tris H C 1 (50 m M , p H
7.4, 1 m M E D T A , 4 0 % glycerol) for between 1-6 weeks prior to analysis. Based on
earlier stability studies of 6HisEDO it was predicted that the mutants would be stable
under these conditions, however, the low V m a x values indicate that this m a y not have
been the case. T o obtain more accurate Vmax values, the enzymes should be analysed
directly after purification, prior to storage at -20°C.

The kinetic data above showed that both Asp274 and His346 resulted in a loss of activity,
whilst I D O carrying mutations at His 16 Val 109 , His 303 , Lys 3 5 2 and sLys 389 retained
enzymatic activity.

5.5.4 Heme binding in human IDO

As previously stated EPR studies have indicated that the proximal heme ligand in IDO
is a histidine residue [16]. This is analogous with a large number of crystallised
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hemoproteins including myoglobin (AC: P02144), hemoglobin (AC: P01922),
leghemoglobin (AC: P42511) and peroxidase (P17179). It has also been proposed,
based on magnetic CD studies, that the distal ligand in IDO may be a histidine residue.
This is analogous to human myoglobin and hemoglobin, which have histidines as both
the proximal and distal heme ligand.

The heme pocket structures of myoglobin and hemoglobin are highly conserved, both
having histidines coordinating to the heme and 28 residues separating these histidines
[6]. It has been shown that the heme pocket of IDO is larger than that found for
myoglobin and hemoglobin, as it allows access to larger molecules such as the inhibitor
Norharman [105]. Spectroscopic studies have indicated that the IDO heme pocket of
IDO more closely resembles that of leghemoglobin (personal communication, Andrew
Terentis, Heart Research Institute, Australia)! 117]. The crystal structure of human
myoglobin (AC: P02144) and leghemoglobin (AC: P42511) are shown in Figure 5.8.
This figure shows the location of the proximal and distal ligands, with myoglobin
(Figure 5.8A) crystallised in the presence of heme and leghemoglobin (Figure 5.8B) in
the absence of heme. The location of the other histidine and aspartic acid residues are

indicated and it can be observed from this that an aspartic acid residue is not directly
involved in the binding of heme in these proteins. The heme pocket in leghemoglobin
is larger than that of myoglobin, and may more closely resemble that of EDO.
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Figure 5.8 Crystal structures of myoglobin and leghemoglobin. The crystals structures of human
myoglobm and leghemoglobin obtained from swiss-protein database, accession numbers are p02144 and
p42511, respectively. The myoglobin heme group is indicated (yellow), the proximal and distal heme
ligands are labelled and indicated (green). All aspartic acids backbones are given in orange and histidines
in purple.
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T o date, studies into the h e m e pocket of I D O have incorporated techniques such as E P R
and magnetic CD analysis. These are indirect methods for the assignment of the
proximal and distal ligands. Site-directed mutagenesis is also an indirect method, which
can identify residues that are required for heme binding, but cannot alone conclusively
determine the role of these residues. The sole conclusive method for the assignment of
the proximal and distal ligand is X-ray crystallography.

The proximal ligand in hemoproteins is essential for keeping the basic and rigid
structure, however, the distal ligand is more easily replaceable by other ligands. It is
therefore proposed that the removal of the proximal ligand by site-directed mutagenesis
should remove the ability of the enzyme to bind heme, whilst the removal of the distal
ligand may not prevent heme binding. The EPR and magnetic CD studies have all
concluded that the EDO proximal ligand is a histidine residue and this is found in a wide
range of hemoproteins. In the EDO and EDO-like myoglobin species there are only three
highly conserved histidines; His , His and His . Of these residues, only the
mutation of His346 resulted in removal of the ability of the enzyme to bind heme. This
shows that His346 is essential for heme binding and activity of human EDO. Since it has
been shown that the proximal ligand in EDO is likely to be histidine and of the highly
conserved histidine residues only His346 was essential for heme binding, it is likely that
His346 acts as the proximal heme ligand in human EDO.

It had been previously proposed by Suzuki et al. [16] that either His346 or His303acts as
the proximal residue. Mutation of His303 did not result in a loss of heme binding ability,
which suggest that His303 is not the proximal ligand. It does not, however, indicate

whether or not it is the distal ligand. This is because whilst the proximal ligand is rigi
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and normally keeps the same position, the distal ligand is more flexible and allows a
replacement with other ligands, including other amino acids. For example if His303 is
the distal ligand, its removal may result in residues such as Met295, Tyr298 or Met299
(which are located near His in the primary sequence and are able to coordinate to
heme) acting as the distal ligand. This His303 mutation does however show that this
residue is not essential for heme binding or activity in EDO.

The Asp274 to alanine mutation resulted in a decreased ability of the EDO mutant to bind
heme. As previously discussed it is possible for aspartic acid residues to be involved in
coordinating the heme through their carboxylate groups. The mutation of this residue
resulting in a loss of enzymatic activity may suggest that this residue is coordinated to
the heme. It has been proposed that the distal ligand in IDO is a histidine [16,117-119].
This proposal is based solely on indirect evidence, i.e. magnetic CD data. Furthermore,
this data has been interpreted differently by two groups. In addition, although histidine
proximal residues are analogous amongst various heme proteins, the distal residues
varies, for example the ligand of cytochrome P-450 is an SH group. It is therefore
possible that Asp274 acts as the distal ligand in EDO.

Mutations of EDO have therefore shown that residues His303, His16, Lys352 and Val109 are
not essential for heme binding in IDO, while His346 and Asp274 are essential for heme
binding. This supports the conclusion that a histidine residue is the proximal ligand in
EDO and suggests that the highly conserved His346 residue may be the proximal ligand.
The Asp274 mutation shows that this residue is essential for heme binding and suggests
that it may be the distal heme ligand. Although these mutations suggest a role for these
residues in the heme binding of IDO, X-ray crystallisation of IDO, or these mutants,
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needs to be undertaken to identify their exact role. If these residues do not directly
coordinate to heme, their removal may compromise the ability of IDO to bind heme by:
(i) Changing the confirmation of the proximal heme ligand so that it cannot coordinate
the heme;
(ii) Altering the conformation of the heme pocket so that it does not allow access to the
heme molecule;
(iii) Altering the conformation of the heme pocket so that it cannot bind the heme
molecule.

His and Asp274 may therefore be directly involved in heme binding by coordination to
the iron, or they may act indirectly by providing support to the heme pocket structure,
thus being essential for the binding of heme in EDO.

5.5.5 Analysis of the sLys389 IDO mutant

An enzymatically-active truncated mutant of human IDO has been produced. The
incorporation of a stop codon at Lys 389 resulted in the expression of a hexahistidyl
tagged and shortened human EDO protein. Enzymatic studies have shown that the
expressed truncated protein, like native IDO and 6HisIDO, has enzymatic activity in the
presence of methylene blue and ascorbic acid.

The production of this truncated IDO mutant suggests that the EDO degradation product
previously described (section 3.3.4) was also enzymatically active. This indicates that
the C-terminal 15 amino acids are not required for enzymatic activity. CD analysis
showed that the sLys389 truncated protein maintained a similar secondary structure to
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6HisED0. This indicates the C-terminal region is probably a flexible region, which is
not highly structured. Thus far, some difficulties have been encountered in obtaining
crystals of 6HisIDO large enough for X-ray structural analysis and this could possibly
be attributed to low levels of degraded protein, or to the presence of a highly mobile
region in the intact IDO. The purification of this sLys389 truncated mutant may aid in
crystallisation studies that are vital for gaining structural information on human EDO

Site-directed mutagenesis of 6HisIDO has therefore produced a shortened protein,
which, with the removal of the C-terminal region, may be more readily crystallised. It
has also provided evidence supporting the proposal that His346 is a heme ligand,
suggesting it may be the proximal ligand, and indicated that His is not the proximal
ligand. Site-directed mutagenesis of Asp274 has shown that it is also required to
maintain the binding of heme in human IDO and suggests that it may be the distal heme
ligand. This is the first experimental evidence showing that both His346 and Asp274 are
essential for heme binding in EDO.

-138-

Chapter 6
Conclusions
and
future work

Chapter 6: General discussion and conclusions

6. General discussion and conclusions

EDO is an enzyme that is widely distributed in humans, however, to date its exact role is
not fully understood. IDO catalyses the first and rate limiting step of the kynurenine
pathway for tryptophan metabolism. This pathway is physiologically important because

it can alter the level of the essential amino acid L-tryptophan, which is required for ce
growth, and may have a protective role in bacterial [38, 66] viral [62-65] and microbial
infections [51]. Products of this pathway are neurotoxic and have been implicated in a
number of disease states [51-57]. The role of IDO, in metabolising the least abundant
amino acid and producing compounds implicated in numerous diseases, is of great
interest. An understanding of EDO's structure may assist the development of inhibitors,
which may provide information into the aetiology of a variety of diseases and possible
drug treatment leads. The development of these inhibitors may provide information into
the aetiology of a variety of diseases and possible drug treatment leads.

Prior to this study human EDO was only purified in small quantities. An expression and
purification system that produces enzymatically active human EDO needed to be
developed. The hexahistidyl expression system was chosen because the incorporated

6His tag is short and protease cleavage of the tag is usually unnecessary for obtaining a
functional recombinant protein [48, 49]. Human IDO cDNA was cloned into the
expression plasmid pQE9 and transformed into E. coli EC538 (pREP4). The resultant
EC538 (pREP4, pQE9-IDO) expressed a 47 kDa protein, which was confirmed to be
human IDO by Western blot analysis.
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6HisIDO was purified from E C 5 3 8 (pREP4, p Q E 9 - I D O ) crude lysate using a protocol
based in part on that previously reported for purifying human placental IDO. This
purification process used sonication to lyse the cells and a combination of cation
exchange and Ni-NTA affinity chromatography to purify 6HisEDO. This expression
and purification system was optimised by the addition of hemin during expression and
the protease inhibitors PMSF and EDTA during expression and purification.
Purification in this manner resulted in the production of a homologous band by SDSPAGE analysis. Mass spectral analysis of this protein gave a molecular ion at the
expected molecular weight of 46 967 Da. Characterisation of the recombinant human
EDO showed it to be essentially identical to the native human enzyme in terms of
spectroscopic properties, cofactor dependency, substrate specificity and molecular
activity. This system therefore established a reliable source of functional human EDO.
Availability of this enzyme would facilitate not only the elucidation of the structure of
human EDO but also provide a source of enzymatically active IDO to aid ligand based
inhibitor design.

Further research was undertaken to gain additional structural information on 6HisEDO
and to develop and characterise mutant EDO proteins. The analysis of 6HisEDO
provided insight into the stability and the secondary structure of 6HisEDO and also
resulted in the formation of human IDO crystals. Although, to date, the crystals

obtained are too small for X-ray diffraction, the identification of a system that promotes
crystal growth is very promising for the elucidation of the IDO crystal structure.

The development and analysis of site-directed mutants of IDO provided information
about the heme binding characteristics of IDO. Replacement of His303, His and His ,

-140-

Chapter 6: General discussion and conclusions

the only highly conserved histidines in E D O and IDO-like myoglobins, were developed.
Conversion of His to Ala, resulted in a loss of heme binding to the enzyme, while the
secondary structure of the protein was maintained. This mutant therefore provides
supportive evidence for the proposal that a histidine, specifically His346, is the proximal
heme ligand in EDO. Mutation of His303 to Ala, did not remove the ability of the
enzyme to bind heme, indicating that His303 is not the proximal heme ligand. Sitedirected mutagenesis showed that Asp274 is also required for the binding of heme in
EDO. This suggests that Asp274 may be the distal ligand. The role of His346 and Asp274
in the binding of heme in EDO may be direct, i.e. they may act as the proximal and distal
heme ligands. It may be however that they act indirectly by providing support to the
heme pocket structure, or that they are important in the conformation or tertiary
structure of the heme ligands, thus being essential for the binding of heme in EDO.
Crystallisation of EDO, or of these mutants, will directly determine their role in the
heme binding of IDO.

Site directed mutagenesis also allowed the production of a C-terminally shortened
mutant protein. The analysis of this truncated protein showed that it maintained
enzymatic activity and secondary structural integrity, indicating that the C-terminal
region of EDO may be a highly mobile region, consistent with its cleavage in vivo. The
removal of this mobile region may thus aid crystallisation. Future crystallisation
experiments will therefore focus on crystallising the sLys389 truncated protein. This is
because the presence of a highly flexible region would hinder crystallisation and it has
already been shown that this truncated protein maintains enzymatic activity. Also, the
purification of the pure sLys389 IDO mutant over full-length 6HisEDO may be
preferential, because of the possibility that the purified 6HisEDO may still contained
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traces of the degradation product, (as described in Chapter 4) and that this degradation
product is hindering crystallisation.

The project may also be extended by production of 6HisEDO as a N15 labelled protein,
which may allow for the determination of residues surrounding the heme group using
NMR spectroscopy. Site-directed mutagenesis could also be extended to mutate the
other His residues in EDO to confirm that they are not coordinated to the heme. In
addition to these experiments, the His346, His303 and Asp274 mutants could be further
analysed by EPR. This may provide more of an insight into how these residues are
involved in heme binding in IDO.

The 6HisEDO protein provides the basis of a viable in vitro testing system for screening
potential EDO inhibitors. The use of the in vitro IDO assay using 6HisEDO would aid
inhibitor design from a ligand-based approach.

In conclusion, this research has established the first efficient expression and purificati
system for producing enzymatically active human IDO. The production of this protein
has allowed for structural analysis of IDO and has provided the first crystals of human
EDO. It has also provided evidence to support the proposal that His346 is the proximal
ligand (His346) and indicated that His303 is not the proximal ligand. Site-directed
mutagenesis has extended the knowledge of heme binding, showing that Asp274 is also a
requirement for heme binding in the human enzyme. This work will also extend the
availability of human IDO to researchers and has provided an increased insight into the
heme environment of the enzyme. This information will facilitate the design of more
potent IDO inhibitors by aiding both ligand and structure- based inhibitor design.
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Media

IB (500 ml)
Tryptone
Yeast extract
NaCl

10 g
5g
5g

IB plates (500 ml)
Tryptone
Yeast extract
NaCl
Agar

10 g
5g
5g
7.5 g

Antibiotic concentrations
Ampicillin
Kanamycin

100 pig / m L
50 pig / m L

SOB(lOOml)
Tryptone
Yeast extract
NaCl (1M)
KC1 (1M)

2g
0.5 g
1 mL
0.25 m L

SOC (100ml)
SOB
MgCl2.6H20 (1M), MgSO4.7H20 (1 M )
Glucose (2 M )
Storage ofE. coli cells
Casamino acids
Glycerol

97 m L
1 mL
1 mL

1%
10%0

Buffers

TE buffer (pH 8)
Tris-HCl
Ethylenediamine-tetraacetic acid (EDTA)
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Phosphate buffered saline (PBS) (lOx)
NaCl
KC1
Na 2 HP0 4
KH 2 P0 4
Potassium phosphate buffer (KPB) (500mM, pH 7.4)
K H 2 P 0 4 (1M)
K 2 HP0 4
dH 2 0

80 g/L
2 g/L
11.15 g/L
2 g/L
95 m L
405 m L
to 1L

SDS-PAGE electrophoresis

SDS-running buffer (5x, pH 8.3)
Tris base
Glycine
SDS
Sample cracking buffer
Tris-HCl (pH 6.8)
SDS
(3-mercaptoethanol
Glycerol
Bromophenol blue
Rapid Coomassie blue stain
Coomassie blue R-250
Methanol
Glacial acetic acid
dH 2 0

15 g/L
72 g/L
5 g/L
60 m M
1%
1%
10%
0.01%
0.02%
40%
1°°/°
t0 L
1

Rapid destain
Methanol
Glacial acetic acid
dH 2 0

40 /o

°
l°0//°

t0 l L

Final destain
Glacial acetic acid
Glycerol
dH 2 0

10O//0
°
4%
t0 1 L
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12% Acrylamide gels
dH 2 0
SDS (10%)
40% acrylamide
Tris-HCl (1.5 M, pH 8.8)
TEMED
APS (10%)

2.25 mL
50 uL
1.55 mL
1.25 mL
25 pL
25 uL

4% Stacking gels
0H2O
SDS (10%)
40% acrylamide
Tris-HCl (0.5 M, pH 6.8)
TEMED
APS (10%)

1.57 mL
25 uL
2.75 mL
625 uL
12-5 ML
12.5 pL

Asarose electrophoresis

TAE buffer (lOx, pH 8)
Tris base
Glacial acetic acid
EDTA (0.5M, pH 8)
dH 2 0

48 44

^
11.42 mL
20 mL
t0 l L

Agarose gel
Agarose
TAE

8.5%
lx

DNA Sequence Solutions

TBE (lOx, pH 8.3)

16.2 g
8.25 g
1.2 g

Tris base
Boric Acid
EDTA
DNA sequencing gels (48cm)
Urea 28.8 g
Acrylamide (40%)
TBE (lOx)
MQH20
APS (10%)
TEMED

8.48 m L

8mL
up to 80 m L
400 pL
55 pL

145

Appendix 1 Media and buffers

DNA Sequence loading dye
Formamide EDTA (25 mM)/blue dextran (50 mg/mL)

5x
1x

Western hybridisation solutions

Western transfer buffer
Tris-base
Glycine
Methanol
dH 2 0

3.1 g/L
I4.4 g/L
200 mL
to 1L

Western blocking solution
Low fat instant milk powder (Dutch Jug)
PBS
Western development solution
Solution 1
H202
dH 2 0
Solution 2
4-chloro-l-napthol
Methanol

5%
lx

30%
to30mL

30 m

8

10 mL

Site directed mutasenesis buffers

Annealing buffer
Tris-HCl (pH 7.5)
MgCl2
NaCl

200 mM
100 m M
500 mM

Synthesis buffer
Tris-HCl (pH 7.5)
dNTPs
ATP
DTT

100 mM
5mM
lOmM
20 mM
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